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“… to myself I seem to have been only like a boy 
playing on the seashore, and diverting myself in 
now and then finding a smoother pebble or a 
prettier shell than ordinary, whilst the great ocean 
of truth lay all undiscovered before me.” 
 
Sir Isaac Newton 
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SOMMARIO	  
I transfer RNA (tRNA) sono piccole molecole di circa 70-80 nucleotidi, che hanno 
un ruolo cruciale nella sintesi proteica. Le molecole di tRNA sono altamente 
modificate a livello post-trascrizionale; la metilazione di residui nucleotidici è una 
delle modificazioni più comuni. Diversi enzimi sono responsabili della 
modificazione di tRNA e la loro funzione è essenziale per il mantenimento delle 
funzioni cellulari in quanto può regolare la stabilità, l’aminoacilazione e la rigidità 
della struttura del tRNA. I tRNA, quando de-aminoacilati o degradati in frammenti, 
sono importanti molecole di segnalazione all’interno della cellula e possono 
attivare diversi pathways di risposta a condizioni di stress. Per questo motivo non è 
sorprendente che mutazioni in diversi enzimi che modificano il tRNA siano state 
associate a patologie di diversa natura nell’uomo. Diversi polimorfismi del gene 
CDKAL1, codificante la proteina Cdk5 regulatory associated protein 1, sono stati 
associati a diabete di tipo 2 (T2D) nell’uomo. CDKAL1 codifica per una metil-tio 
transferasi che modifica il residuo 37 in tRNA che riconoscono il codone UUU 
specifico per l’aminoacido Lisina. E’ stato dimostrato che l’assenza di CDKAL1 e, 
di conseguenza, della modificazione catalizzata dall’enzima induce una 
diminuzione dell’efficienza di incorporazione di residui di lisina nella pro-insulina, 
importanti per la corretta maturazione, a livello delle cellule beta del pancreas. 
Questo provoca la diminuzione della maturazione di pro-insulina in insulina e 
peptide-C, con difetti nella secrezione di insulina glucosio-dipendente. Inoltre 
l’assenza di CDKAL1 porta all’aumento di markers di stress del reticolo 
endoplasmico. L’attivazione dei processi di stress del reticolo endoplasmico induce 
il blocco della sintesi proteica e l’attivazione cronica innesca pathways pro-
apoptotici. Questi eventi sono alla base dello sviluppo del diabete di tipo 2.  
Il presente lavoro ha lo scopo di studiare il ruolo di enzimi che modificano il tRNA a 
livello delle beta cellule pancreatiche e di investigare le conseguenze di mutazioni 
in questi enzimi sulla funzione e la sopravvivenza cellulare.  
L’Iperinsulinismo Congenito è una malattia rara, caratterizzata da un’inappropriata 
secrezione di insulina che causa ipoglicemia. Mutazioni in nove geni sono state 
precedentemente individuate come causative della malattia, nonostante la causa 
genetica sia ancora ignota nel 50% dei pazienti. Uno studio di Whole Exome 
Sequencing in pazienti di Iperinsulinismo Congenito, attuato precedentemente nel 
nostro laboratorio, ha portato all’individuazione di una lista di geni candidati. 
L’utilizzo di strumenti bioinformatici mi ha permesso di identificare CDKAL1 come 
uno dei candidati più promettenti. La mutazione individuata porta alla sostituzione 
S561F con probabili conseguenze sul dominio transmembrana della proteina, che 
ne assicura la localizzazione nel reticolo endoplasmatico. Allo scopo di studiare le 
conseguenze della variante di CDKAL1 sulle beta cellule, ho utilizzato tecniche di 
biologia molecolare per indurre l’overespressione del gene wild type e mutato nella 
linea cellulare INS-1E, modello di beta cellule ampiamente utilizzato derivata da 
insulinoma di ratto. La localizzazione di CDKAL1 è stata valutata con l’utilizzo di 
microscopia ad immunofluorescenza; è stato quindi dimostrato che la variante 
S561F di CDKAL1 altera la localizzazione della proteina, che, nonostante sia 
ancora inserita nella membrana del reticolo endoplasmico, tende ad accumularsi in 
strutture vescicolari in alcune zone della membrana. Per saggiare le conseguenze 
della mutazione sulla funzione delle beta cellule, ho valutato il contenuto e il 
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rilascio di insulina. L’overespressione di CDKAL1 porta ad un aumento del 
contenuto di insulina. Questo effetto non è stato invece osservato in cellule che 
overesprimono la variante S561F, che induce in contrasto un aumento nella 
secrezione basale (non stimolata da glucosio) di insulina. Questi dati preliminari 
suggeriscono che la variante S561F di CDKAL1 possa avere un ruolo nello 
sviluppo delle disfunzioni della beta cellula che provocano un’alterata secrezione 
insulinica. 
La metiltransferasi TRM10 è un enzima che modifica tRNA in lievito. Una 
mutazione nel gene omologo umano TRMT10A che porta all’inserimento di un 
codone di stop e alla conseguente assenza della proteina è stata identificata in 
pazienti affetti da microcefalia e diabete con insorgenza giovanile. E’ stato 
dimostrato che TRMT10A è una metiltransferasi anche in cellule umane e che 
modifica residui di guanina. L’assenza della proteina a livello di cellule 
pancreatiche provoca un aumento dell’apoptosi in condizioni basali e sensibilizza 
le cellule ad apoptosi indotta da stress del reticolo endoplasmico. Il mio lavoro ha 
come scopo l’identificazione delle conseguenze dell’assenza di TRMT10A sulle 
modificazioni e la stabilità di molecole di tRNA. Le molecole di tRNA specifiche per 
glutammina e metionina sono risultate essere modificate da TRMT10A in cellule 
umane e lo sviluppo di una tecnica di northern blot ha fornito dati preliminari 
riguardo alle conseguenze dell’assenza dell’enzima sull’aminoacilazione e la 
stabilità del tRNA. Lo studio dei meccanismi che portano alla morte cellulare, 
attivati dall’assenza di TRMT10A, è stato inoltre approfondito nel presente lavoro. 
A questo proposito è stata utilizzata le linee cellulari INS-1E e EndoC-	  βH1, linea 
cellulare umana, in cui è stato indotto il silenziamento del gene TRMT10A. I 
risultati ottenuti dimostrano che l’assenza di TRMT10A induce un aumento 
dell’apoptosi mediante l’attivazione del pathway intrinseco dell’apoptosi tramite 
l’attivazione della proteina pro-apoptotica Bim e l’aumento dell’attivazione di 
caspasi a valle.  
Il lavoro svolto durante il mio dottorato apporta un avanzamento nella 
comprensione dell’importante ruolo di enzimi che modificano il tRNA nel 
mantenimento della funzione e sopravvivenza delle beta cellule pancreatiche.  
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ABSTRACT	  
Transfer RNAs (tRNAs) are small molecules of 70-80 nucleotides with a crucial 
role in protein synthesis. tRNAs once transcribed are highly modified and the 
methylation is the most common modification. Several enzymes are responsible of 
tRNA modification and their function is necessary to regulate the stability, the 
aminoacylation and the rigidity of the structure of tRNAs. De-aminoacylated or 
degraded tRNAs can act as important signal molecules in the cells, activating 
different pathways of stress response. For this reason is not surprising that 
mutations in genes codifying for tRNA modifying enzymes have been associated to 
many human diseases. Polymorphisms in the gene CDKAL1, codifying the Cdk5 
regulatory associated protein 1, have been linked to the development of type 2 
diabetes (T2D) in human. CDKAL1 is a methyl-thio transferase that modifies the 
residue in position 37 of tRNAs, which recognize the codon UUU for lysine. The 
absence of CDKAL1, and consequently of the modification catalyzed by the 
enzyme, was shown to induces a decrease of incorporation of lysine residues in 
proinsulin at the level of pancreatic beta cells. Lysine residues are crucial for the 
correct maturation of proinsulin. It was shown that the absence of CDKLA1 
mediated modifications leads to defects in the processing of proinsulin to produce 
insulin and c-peptide and to impaired glucose-stimulated insulin secretion. 
Furthermore in CDKAL1 knock out beta cells it’s observed an increase of markers 
of endoplasmic reticulum (ER) stress. The chronic activation of ER stress 
processes decreases the general protein synthesis and the chronic activations 
triggers pro-apoptotic pathways. These events have been linked to the 
development of T2D.  
The aim of the present work is to study the role of tRNA modifying enzymes in 
pancreatic beta cells and to investigate the consequences of mutations in these 
genes on cell function and survival.  
A Whole Exome Sequencing study performed previously from my group produced 
a list of candidate genes for Congenital Hyperinsulinism (CHI). CHI is a rare 
disease, characterized by inappropriate insulin secretion leading to hypoglycemia. 
Mutations in nine genes are already known to be causative of the disease, but in 
50% of patients the genetic cause is unknown. Using bioinformatics tool I identified 
CDKAL1 as one of the most promising candidate genes. The mutation identified 
leads to the substitution of a Serine with a Phenylalanine in position 561, with 
probable consequences on the transmembrane domain that ensures the correct 
localization of the protein in the membrane of the ER. In order to study the 
consequences of S561F CDKAL1 variant in beta cells, I used molecular biology 
techniques inducing the overexpression of wild type and mutated gene in INS-1E 
cell line, derived from rat insulinoma. The localization of CDKAL1 was analyzed by 
immunofluorescence microscopy: the S561F variant affect the localization of the 
protein that, although still inserted in the ER, tends to accumulate in vesicular 
structures in some regions of the ER membrane. I also studied the impact of 
S561F CDKAL1 overexpression on the beta cell function, by measuring the 
content and the release of insulin in basal growing conditions. I observed an 
increase of insulin content induced by the overexpression of the wild type protein 
while the insulin release was not changed. On the other hand, the S561F variant 
doesn’t affect the insulin content that doesn’t change compared to not-transfected 
	   	  6	  
cells, but induces an increase in insulin release. These preliminary results suggest 
that the S561F CDKAL1 variant could have a role in the development of beta cell 
dysfunction leading to an inappropriate insulin secretion. 
The second part of my project regards the methyl-transferase TRMT10A. A 
mutation in this gene - the insertion of a stop codon and consequent absence of 
mature protein - was identified in patients affected by microcephaly and young 
onset diabetes. It was demonstrated that TRMT10A modifies guanine residues, but 
its role in tRNA modification in human is still not demonstrated. The absence of the 
protein leads to an increase of cell death in basal conditions and sensitizes cells to 
ER stress-induced apoptosis. My work aimed at the characterization of the 
consequences of TRMT10A deficiency on tRNA modification and stability. I used 
lymphoblast cells derived from controls subjects and patients to investigate this 
tRNAs molecules specific for glutamine and methionine were identified to be 
modified by the enzyme, and the development of a northern blot technique allowed 
me to obtain preliminary on the aminoacylation and stability of these molecules in 
TRMT10A deficiency conditions. Furthermore I investigated the mechanisms that 
lead to beta cell death, triggered by the absence of the protein. With this purpose I 
induced the silencing of the gene in two different cell lines: INS-1E and EndoC-	  
βH1 (human beta cell line). Results obtained demonstrated that TRMT10A 
deficiency triggers the activation of the intrinsic pathway of apoptosis through the 
modulation of Bim expression, a proapoptotic protein of the BH3-only family. The 
results obtained highlighted the importance of TRMT10A for the survival of the 
beta cells. Furthermore the activation of the intrinsic pathway of apoptosis is one of 
the events observed in the development of type 2 diabetes. These findings can 
give additional proves that the monogenic forms of diabetes can be used as model 
for the study of mechanisms involved in type 2 diabetes.  
Even if further investigations on the complex processes involved are needed, the 
present work provides important evidences of the role of tRNA modifying enzyme 
in beta cell homeostasis. Moreover recent reports about the role of tRNAs in 
signalling pathways support the hypothesis that these molecules can be important 
mediators of stress response in beta cells, and the tRNA modifying enzymes may 
act as activators or inhibitors of these responses.   
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1 INTRODUCTION 
1.1 Diabetes mellitus 
Diabetes is characterized by insulin deficiency and consequent 
hyperglycemia due to progressive failure of pancreatic beta cells. The 
worldwide incidence of diabetes reached epidemic proportions, with nearly 
300 million of people affected (http://www.idf.org). There are two major 
forms of diabetes; the most diffused form is type 2 (80-85% of patients), 
while type 1 represents the 10-15% of cases. Several genetic 
polymorphisms are associated to diabetes, but also specific environmental 
factors, such as viral infections for T1D and obesity for T2D, participate to 
the development of the disease. The failure of pancreatic beta cells is a 
consequence of different mechanisms in the two forms of diabetes. T1D is 
an autoimmune disease characterized from mononuclear cells infiltration in 
pancreatic islets and instauration of chronic inflammation (insulitis). Beta 
cells are progressively destroyed with the loss of most of 70-80% of beta 
cell mass at the time of diagnosis; this process is triggered by direct contact 
with immune system cells and through signals released from these cells 
such as proinflammatory cytokines: interleukin (IL)-1β, tumor necrosis 
factor (TNF)-α and interferon (IFN)-γ1. T2D results from alteration of 
glucose stimulated insulin secretion that is caused from dysfunction of beta 
cells. Loss of β-cell mass can also play a role in the development of T2D, 
since post-mortem studies have shown a 25-50% mass reduction2 and 
increased apoptosis3. High glucose and saturated free fatty acid derived 
from diet are risk factors for T2D and can activate intracellular pathways 
that lead to apoptosis4.  
In both forms of diabetes beta cell death is a consequence ER stress 
and/or activation of the intrinsic pathway of apoptosis. While the extrinsic 
pathway of apoptosis begins outside the cells through the activation of 
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death receptors by pro-apoptotic signals, the intrinsic pathway involves 
non-receptor–mediated intracellular signals, inducing activities in the 
mitochondria that initiate apoptosis. The Bcl-2 protein family plays a central 
role in this process. Bcl-2 proteins are classified in three categories: the 
pro-survival (Bcl-2, Bcl-XL, Mcl-1, Bcl-W and A1), the pro-apoptotic (Bax, 
Bak and Bok) and the Bcl-2 homology 3 (BH3)-only proteins subfamily. The 
activation of apoptosis pathway is a matter of balance and interactions 
between these proteins. Bax and Bak are the real effectors of cell death 
and their activation is a crucial event. Bax exists as inactive monomer in 
the cytosol while Bak is always inserted in the mitochondrial outer 
membrane (MOM) and kept inactive by the interaction with VDAC2. BH3 
activators induce the oligomerization of Bax and the insertion in the MOM, 
where it disrupts the interaction between Bak and VDAC2, allowing Bak 
oligomerization. These events lead to the formation of pores in the MOM 
and the release of pro-apoptosis factors such as cytochrome c and 
SMAC/DIABLO5. Citochrome c in the cytoplasm binds to APAF1 and 
triggers the formation of the apoptosome that activates pro-caspases, 
proteases that cleave important proteins through the cell6 (Figure 1).  
The pathways that induce apoptosis are cell and context specific. In T1D 
cytokines released from immune system cells bind to beta cells receptors 
inducing intracellular responses. IL-1β activates the transcription factor NF-
kB that modulates the expression of several genes, including cytokines, 
chemokines and iNOS (nitric oxide synthase)4. IFN-γ binding with cell 
surface receptors induces JAK1 and JAK2 kinases that phosphorylate and 
activate STAT1 transcription factor. The activation of IFN-γ dependent 
pathways have a synergic effect on IL-1β induced cellular responses, 
triggering different mechanisms that can lead to beta cell death. One of the 
mechanisms involves the member of the MAPK family c-Jun NH2-terminal 
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kinase (JNK) that phosphorylates c-Jun inducing the upregulation of DP5 
sensitizer BH3 protein. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Another mechanism involved in cytokines induced apoptosis is the ER 
stress response that is triggered by NO production via PERK activation. ER 
stress response leads to apoptosis through the decrease of Mcl-1, pro-
survival Bcl-2 protein,7 and increase of expression of DP5 and PUMA, 
BH3-only activator8. ER stress is a process by which cells respond to the 
disruption of ER homeostasis. Different factors can induce an accumulation 
of unfolded proteins in the ER, such as mutations that affect proteins 
folding or lack of chaperon proteins activity, leading to the activation of the 
unfolded protein response (UPR). The role of the UPR is to contrast ER 
Figure 1: schematic representation of 
Bcl-2 proteins interactions. There are 
two groups of BH3-only subfamily 
members; DP5, Bad, Bik, Bnip3, Bmf 
and Noxa are named sensitizers and 
act by binding the pro-survival Bcl2 
proteins promoting the release of 
BH3-only activatprs Puma Bim and 
tBid. The activators bind the pro-
apoptitic effectors Bax, Bak and Bok 
triggering the mitochondrial pathway 
of apoptosis68. Image adapted from 
Gurzov E.N. and Eizirik, D., 2011. 
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stress by attenuating the general protein translation and the consequent 
overload of proteins in the ER and triggering the degradation of misfolded 
proteins9. In parallel, the UPR induces the expression of genes, involved in 
the restoration of ER homeostasis, such as chaperons. If the UPR fails in 
attenuate ER stress the apoptosis pathway is induced. Three proteins 
inserted in ER membrane are important mediators of the UPR: inositol 
requiring ER-to-nucleus signal kinase (IRE) 1, activating transcription factor 
(ATF) 6 and double-stranded RNA-activated kinase (PKR)- like ER kinase 
(PERK). These proteins are associated to the chaperon protein Bip and 
maintained inactive. In presence of unfolded protein Bip dissociates to 
participate in the protein folding, inducing the activation of the trans-
membrane proteins10. IRE1α mediates the splicing of the Xbp-1 
transcription factor (bZip protein). Spliced XBP-1 enters the nucleus and 
modulates the transcription of unfolded protein response (UPR) target 
genes, including ER chaperones; moreover IRE1α induces the 
phosphorylation of JNK and consequently the activation and upregulation 
of DP5 via c-Jun triggering the mitochondrial apoptosis pathway11. ATF6 
once activated by ER stress can translocate to the Golgi, where is cleaved, 
and then to the nucleus. ATF6 is a transcription factor that binds ER stress 
response elements (ERSE) in genes codifying for chaperon proteins12. 
ATF6 and IRE1α pathways are strictly connected: ATF6 increase the 
mRNA expression of XBP-1 increasing the substrate of IRE1α13. PERK is 
protein kinase inserted in the ER membrane that directly phosphorylates 
the eukaryotic initiation factor 2 alpha (eIF2α) leading to the inhibition of 
total protein synthesis (Figure 2). When eIF2α is phosphorylated the 
transcriptional factor ATF4 gene is specifically transcribed and induces the 
expression of CHOP that seems to contribute to the activation of 
mitochondrial pathway of apoptosis, even if the mechanism is still not 
clarified. Other kinases can phosphorylate eIF2α in response to different 
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kind of stress: PKR is a sensor of double strand RNA, GCN2 is activated by 
de-aminoacylated tRNAs in aminoacid deprivation condition and by UV 
light, HRI mediates the response to heme deficiency and oxidative stress14 
(Figure 3).  
 
   
Figure 2: Unfolded protein response. The image from Chen, Y. and Brandizzi, F. 2013 
shows the three arms of the UPR signaling that involves to activation of PERK, IRE1 
and ATF6 pathways11. 
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In T2D the apoptosis is induced mainly from free fatty acid (FFA) and high 
glucose; ER stress response seems to be play a major role in the activation 
of apoptosis pathways. In the case of lipotoxicity, ER stress can be 
triggered by over-stimulation of FFA esterification in the ER that leads to 
delay in the export of proteins and high glucose can sensitize the cells to 
HRI PERK GCN2 PKR 
Heme deficiency, 
Oxidative stress ds RNA 
Amino acid 
deprivation, UV 
Unfolded protein 
response, Hypoxia 
eIF2α 
GLOBAL PROTEIN TRANSLATION OFF 
ATF4 TRANSLATION ON 
Figure 3: Representation of eIF2 kinases activated by different cellular stress stimuli. The 
heme regulated inhibitor (HRI), the RNA-dependent kinase (PKR), the PKR-like ER kinase 
(PERK) and the general control non-derepressible 2 (GCN2) can phosphorylate the 
Eukaryotic Initiation Factor 2 at the level of the subunit α. the phosphorylation of eIF2α 
induces the inhibition of general translation and the preferential translation of transcription 
factors (e.g. ATF4) that initiate a pattern of gene expression that allows the cell to respond 
to the stress. 
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ER stress by increasing the secretory demand4. However several and 
complex events can lead to ER stress and activation of UPR in beta cells, 
the mechanisms remain to be elucidated. The described events that lead to 
development of T2D are triggered by stress conditions, but polymorphisms 
in several genes contribute to the predisposition to the disease modulating 
the response to environmental stimuli. Monogenic forms represent a third 
category of diabetes and comprise single gene disorders with different 
phenotypes unrelated to auto-immunity. Genes causing monogenic forms 
of diabetes are involved in developmental and/or functional processes of 
the pancreatic beta cell physiology. Different genes causative of monogenic 
forms of diabetes have been associated to T2D. The identification of gene 
variants and mechanisms leading to monogenic forms of diabetes can 
serve as model for identifying new targets of beta cell demise in T2D. 
1.2 Congenital hyperinsulinism 
An altered insulin secretion characterizes the rare genetic disease 
Congenital Hyperinsulinism (CHI) that causes persistent hypoketotic 
hypoglycemia (i.e. plasma glucose levels <50 mg/dl and low levels of 
ketones) in newborns15. CHI occurs in 1:30000-1:50000 live births, but the 
incidence can be higher in population where consanguineous marriages 
are common16. Hypoglycemia can cause brain damage; children affected 
by CHI can develop neuromotor delay, mental retardation, and epilepsy as 
a consequence of repeated episodes of hypoglycaemia that may also lead 
to death. A rapid diagnosis and appropriate management are essential to 
prevent brain damages17 with interventions aimed at maintaining blood 
glucose within normal range, initially through glucose administration and 
glucagon infusion, and once the diagnosis is set, with specific treatments.  
CHI cases differ for histological characteristics: diffuse forms involve the 
whole pancreas, while focal forms affect a limited pancreatic region (or 
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more than one in very rare multifocal CHI)18. Focal forms can be cured with 
the surgical excision of the lesion identified and localized with specialized 
imaging (18F-DOPA-PET), while diffuse cases may need subtotal or total 
pancreatectomy to control hypoglycemia, with dramatic consequences 
such as diabetes and malabsorption due to deficit of pancreatic enzymes. 
Recently, an “atypical” form of focal hyperinsulinism characterized by 
morphologic mosaicism of pancreatic islets19 has been also described. The 
genes involved in the development of the disease and the type of mutations 
lead to different clinical onset (ranging from mild to severe) of CHI, 
inheritance and histologic. The majority of CHI cases are caused by 
mutations of ABCC8 and KCNJ11 genes placed in the short arm of 
chromosome 11 and encoding the two subunits Sur1 and Kir6.2 of the 
pancreatic beta cell ATP-sensitive potassium channel (KATP). The KATP 
channel participates in the regulation of glucose-dependent insulin 
secretion from the beta cells. In resting conditions the channel is open and 
when plasma glucose raises, glucose metabolism within the beta cell 
induces the closure of KATP channel and the consequent membrane 
depolarization20. These events lead to the opening of voltage gated Ca2+ 
channels, and Ca2+ influx triggers the exocytosis of insulin-containing 
granules. Genetic defects in these genes affect beta cell membrane 
depolarization that leads to glucose-independent insulin secretion. 
Mutations that completely abolish channel function can be heterozygous 
mutations with dominant-negative effect. Recessively inherited mutations in 
ABCC8 and KCNJ11 lead to diffuse and severe forms of CHI, usually not 
responsive to diazoxide and often requiring subtotal or total 
pancreatectomy21. In contrast, patients with dominant-negative 
heterozygous mutations usually respond to medical treatment, and may 
present a later onset of hypoglycemia. Paternally inherited mutations in 
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ABCC8 or KCNJ11 cause the focal forms when a concomitant somatic loss 
of maternal 11p15 allele occurs within limited regions of the pancreas22. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Figure 4: Insulin secretion mechanism in beta cells; Insulin release from beta cells is a two 
phases mechanism: raising levels of circulating blood glucose trigger the first phase that is 
more rapid and immediate compare to the second phase, which consists in a slow response 
involving the formation of new vesicles. In the first phase glucose enters the cells through 
the GLUT2 transporter and is metabolized by glycolysis and Krebs cycle with the production 
of ATP. The ATP sensitive potassium channel is inhibited by the increase of ATP and its 
closure leads to membrane depolarisation. The influx of calcium from voltage gated 
channels and calcium release from the ER is triggered and this stimulates the release of 
secretory vesicles previously synthetized. In the figure are highlighted (in red) the proteins 
codified by genes known to be causative of Congenital hyperinsulinism. Image adapted from 
Seniappan, S. et al 2013. 
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In addition to ABCC8 and KCNJ11 variants, studies identified other genes 
as causative of the disease: autosomal recessive mutations of HADH gene 
and dominant mutations of GCK, GLUD1, SLC16A1, HNF4A, UCP2, 
HNF1A23. All nine genes codify proteins (transcription factors, metabolic 
enzymes and transporters) necessary for the regulation of the glucose-
dependent insulin secretion in pancreatic beta cells - linking the 
mitochondrial glucose metabolism to insulin secretion events (Figure 4). 
The mainstay of medical therapy is diazoxide (DZX), used as a first line 
drug; it binds and activates intact KATP channels, thereby reducing insulin 
secretion. The side effects of this treatment include fluid retention and 
hypertrichosis. However, diazoxide can be ineffective in diffuse CHI due to 
inactivating mutations in ABCC8 and KCNJ11 and in most patients with 
focal CHI. Octreotide is a long-acting analogue of somatostatin (SMS) with 
the ability to inhibit the secretion of several hormones including insulin and 
is utilised when diazoxide fails to control hypoglycemia24. Additional 
medical options include the Ca2+ channel blocker nifedipine, and more 
recently, the GLP-1 receptor antagonist, exendin, that showed the ability to 
acutely elevate fasting blood glucose in individuals with CHI caused by 
ABCC8 mutations25.  
CHI represents the opposite phenotype of monogenic diabetes, which is 
characterized by hyperglycemia of early onset (neonatal 
period/childhood/young adults) due to genetic defects of pancreatic beta 
cell. The two main clinical forms of monogenic diabetes are neonatal 
diabetes (NDM) - diabetes onset within 6 months of birth- and maturity 
onset diabetes of the young (MODY). Interestingly, mutations in genes 
previously identified as causative of MODY or NDM such as GCK26,27, 
HNF4A, and HNF1A,28,29 can cause CHI30,31 while genes that were first 
implicated in CHI, like ABCC8, KCNJ11, have been later found to be 
involved in NDM and MODY32,33. Therefore, the identification of new CHI 
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genes might simultaneously provide clues about new NDM/MODY genes18. 
In addition, numerous studies have demonstrated that some 
polymorphisms in genes causing CHI or monogenic diabetes are also 
associated to type 2 diabetes (T2D), showing that a “gradient” of variants 
links all these conditions, i.e., CHI, NDM/MODY and T2D34. However, it has 
to be noticed that, differently from T2D, NDM and MODY do not have 
insulin resistance as pathophysiological trait. Genetic diagnosis of a patient 
with CHI, along with imaging results, is crucial for the correct clinical 
management (i.e. drug therapy vs surgery, and type, mode and duration of 
drug therapy), but no mutations in known genes are found in a high 
percentage (up to 50% in diazoxide responsive and about 10% of diazoxide 
unresponsive) of patients clinically diagnosed as CHI.  
1.3  Transfer RNA 
Transfer RNAs (tRNAs) are the most abundant RNA molecules in the cell 
(4-10%) and play a key role in protein synthesis process, mediating the 
translation of messenger RNA  (mRNA) codons into specific polypeptides35. 
The function of tRNA in translation is well known since decades but only 
during the last years it has been shown that these molecules don’t act just 
as mediators but have also many functions in signaling and regulation of 
cellular pathways36. Moreover mutations in genes codifying tRNAs or tRNA-
modifying enzymes have been described in different human diseases37. 
The biogenesis of tRNAs is a complex process that involves many steps 
and checkpoints. The RNA polymerase III is responsible of the transcription 
of tRNA genes into precursors molecules that need to be processed, 
spliced, modified and transported to the cytoplasm to participate in 
translation.  
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1.3.1  tRNA structure and function in translation 
Mature tRNAs are 70 – 80 nucleotides molecules and their functionality 
depends on the correct three-dimensional structures. In solution, all tRNA 
molecules fold into a cloverleaf secondary structure (Figure 5 A), 
characterized by four stems – double helices stabilized by Watson-Crick 
base pair interactions; three of the four stems have loops and one contains 
the free 3’ and 5’ ends of the chain. The central loop contains three 
nucleotides of the anticodon domain that forms base pairs with the three 
complementary nucleotides forming a codon in mRNA. Specific aminoacyl-
tRNA synthetases recognize the surface structure of each tRNA for a 
specific amino acid and covalently attach the proper amino acid to the 
acceptor stem. The folded tRNA molecule acquires an L shape with the 
anticodon loop and acceptor stem localized at the ends of the two arms 
(Figure 5 B). tRNA molecules have two basic functions: to bind a particular 
amino acid and to recognize specific codons in mRNA adding the 
aminoacid to a growing peptide chain. The correct folding of the molecule is 
necessary for the interaction with aminoacyl tRNA synthetases, with the 
ribosome subunits and the mRNA codons. During protein synthesis 
initiation the Eukaryotic translation initiation factor 2 (eIF2) bound to a GTP 
molecule and tRNAiMet (ternary complex) associates with a small (40S) 
ribosomal subunit complexed with two other factors, eIF3 and eIF1A, which 
stabilize binding of the ternary complex. Phosphorylation of eIF2 is a 
mechanism that cells use to regulate protein synthesis; this complex is 
unable to bind tRNAiMet, inhibiting protein synthesis. During the elongation 
phase each incoming aminoacyl-tRNA moves through three ribosomal 
sites: the A (aminoacyl), P (peptidyl), and E (exit) sites.  
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1.3.2 tRNA genes transcription 
tRNA genes are repeated in the genome and are organized in clusters 
localized in the nucleolus; this sub-localization suggests a common 
regulation of transcription38. In the human genome there are 513 tRNAs 
genes encoding for 49 isoacceptors (tRNAs with different anticodons 
bearing the same amino acid); 22 tRNA genes are also contained in the 
mitochondrial genome. The presence of a large number of tRNA genes is 
due to the fact that isoacceptors are encoded by family of genes, and can 
exist as different isodonors (tRNAs with the same anticodons but with 
different sequences in the other domains). This variability is not only the 
consequence of the evolution of genome but seems to be the base for 
modulation of tRNAs expression in different cell type or state, affecting the 
efficiency of the RNA polymerase III binding39. The first step of tRNA genes 
Figure 5: The figure shows the secondary structure (A) of tRNA molecules and its folding in 
the typical L-shaped tertiary structure (B). Image adapted from Hori, H. 2014. 
	   	  23	  
transcription consists in the binding of the transcription factor TFIIIC to the 
DNA elements A-box and B-box and the recruitment of the RNA 
polymerase III (Pol III) through the complex TFIIIB. Maf1 negatively 
regulates pol III by a direct interaction and binding the TFIIIB transcription 
factor. Maf1 is phosphorylated in positive growth conditions by PKA and 
TOR dependent kinase Sch9 and dephosphorylated in response to 
different environmental stresses40. The phosphorylation prevents the 
binding to Pol III and allows the active transcription of tRNAs genes.  
1.3.3  tRNA processing and modification 
Several events lead to the maturation of pre-tRNAs to functional molecules. 
Once tRNA is transcribed is processed by the cleavage of the 5’ leader 
sequence catalyzed by RNAseP enzyme. The 3’ trailer sequence is 
cleaved by endonucleases (Ribonuclease Z) and modified with the addition 
of the CCA end by ATP(CTP)-tRNA-specific nucleotidyl-transferase. tRNAs 
genes are characterized by introns between the nucletides 37 and 38 that 
are removed by tRNA splicing endonucleases and ligases38.  
The most complex characteristic of tRNA maturation process is the large 
number of modifications that can be found in almost 12% of nucleotide 
residues. In figure 6 are illustrated all the known tRNAs modifications, but 
different tRNAs have different set of modifications, that can also vary in a 
tissue specific way or basing on the cell growth state. tRNA modifications 
can have very different chemical nature and are catalysed by a diversity of 
enzymes, however the most common is the methylation of nucleotide 
residues. Modifications at the level of the anticodon domain or in close 
residues (residues 34 and 37) can affect the accuracy and efficiency of 
translation, modulating the codon recognition and translational frameshift 
(codon-anticodon wobbling)41. Modifications in the body of the molecule are 
very important for the folding and the stability; as an example modifications 
	   	  24	  
found at the core of the folded RNA, are thought to predominantly affect the 
structure rigidity or flexibility. Increased rigidity is a consequence of 
pseudouridine residues.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
tRNA biogenesis is controlled at different levels. A nuclear surveillance 
system leads to the degradation of pre-tRNAs that show defects in the 
processing, while hypomodified molecules are eliminated in the cytosol. 
Only correctly modified tRNAs are charged with the specific cognate 
aminoacid and can participate to the protein translation process. 
tRNA charging process takes place in the cytoplasm by the action of 
aminoacyl-tRNA synthetases. The synthetase binds ATP and the 
Figure 6: Summary of all known modifications at the level of nucleotide residues 
in tRNA molecules.  Image adapted from Phizicky, E. M. and Hopper, A. K. 2010. 
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corresponding amino acid to form an aminoacyl-adenylate. The complex 
then binds the appropriate tRNA molecule, and the amino acid is 
transferred to either the 2'- or the 3'-OH of the last tRNA nucleotide (A76) at 
the 3'-end. aminoacyl-tRNA synthetases are characterized by a catalytic 
domain and an anticodon binding domain that recognise the correct tRNA 
molecule. Some enzymes contain additional RNA binding domains and can 
edit incorrectly charged tRNA by cleavege42. Mitochondrial encoded tRNAs 
are aminoacylated within the organelle, even if some nuclear encoded 
tRNAs are imported from the cytosol. 
1.3.4  tRNAs as signaling molecules  
tRNA molecules are involved in different mechanisms used by the cells in 
response to environmental stresses.  
Under nutrient deprivation conditions cytoplasmic tRNAs are reimported in 
the nucleus with the consequent repression of general protein translation. 
Non-charged tRNA molecules still in the cytoplasm bind and activate GCN2 
protein kinase that phosphorylates eIF2α triggering the cellular stress 
response pathway, with the inhibition of general protein synthesis and 
activation of translation of the mRNA encoding the activating transcription 
factor 4 (ATF4)43. Recent studies have described newly identified pathways 
activated under specific cellular growth conditions that lead to the cleavage 
of tRNA molecules at the level of the anticodon loop. Different stress 
conditions (oxidative stress, heat shock, UV irradiation) trigger the cleavage 
of tRNAs with the production of small molecules (30-40 nucleotides) called 
tiRNAs44. Angiogenin is the enzyme responsible of this process in human 
cells; it recognizes preferentially tRNAs with CA sequence in the anticodon. 
The cleavage at the level of the anticodon generates two tRNA halves and 
it has been shown that only the 5’ tiRNAs, and not the 3’ tiRNAs, are able 
to inhibit protein translation. This process is eiF2a-phosphorilation 
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independent and leads to the formation of stress granules45. The function of 
tiRNA in the inhibition of protein translation is similar to the function of 
microRNA and small interfering RNA (siRNA) by displacing eukaryotic 
translation initiator factor 4E (eiF4E) and eiF4G46. Intriguingly under stress 
conditions tiRNAs can interact with specific siRNAs promoting the 
expression of stress response genes47. It’s interesting to notice that tRNA 
halves can be found in serum circulating as part of nucleoprotein 
complexes, suggesting the importance of tRNAs as signaling molecules 
and a possible use as biomarkers since the circulating pool changes with 
age48. In addition of tRNA halves, smaller fragment of 13-30 nucleotides 
have been identified in different species. These fragments can derive from 
a cleavage of D-loop and T-stem by the angiogenin. It has been shown that 
small tRNA fragments can repress translation with a microRNA-like 
activity36. 
1.4 tRNA modification and human diseases 
tRNA molecules play a central role in the regulation of translations under 
different cell growth conditions and can act as signaling factors for the 
activation of cellular pathways. It was also shown that some modifications 
modulate the translation of only some mRNAs that are enriched in specific 
codons; this could represent the way by which the cells modulate the 
synthesis of proteins involved in the same pathway49. Nucleotide 
modifications are necessary for the correct biogenesis, structure and 
function of tRNAs suggesting that the absence of tRNA modifications could 
be deleterious for cells function and survival. Several reports during the last 
years demonstrated the involvement of mutations of tRNA genes and tRNA 
modifying enzymes in human diseases37. Table 1 from Torres et al, 2014 
represents a summary of all human disorders linked with mutations of tRNA 
modifying enzymes that have been associated with different disease 
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categories: neurological, cardiac, respiratory, cancer, metabolic and 
mitochondrial linked. Even if the process of tRNA modification occurs in 
every cell type and stage, the mutation of some tRNA modifying enzymes 
affect only subtypes of cells and organs. This is a consequence of 
transcriptional modulation of tRNA modifying genes that show increased 
expression in certain tissues or development stages. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Disease&category Disease Affected&tRNA&modificationGene&involved Refs
Neurological Intellectual)disability 20O2methylribose FTSJ1)
Freude,)K.)et)al)2004;))))))))))))))))))))))))))))))
Takano,)K.)et)al)2008;))))))))))))))))))))))))))))))))
Gong,)P.)et)al)2008
m22G TRM1 Najmabadi,)H.)et)al)2011
m5C NSUN2 Abbasi2Moheb,)L.)et)al)2012;)))))))))))))))))))Khan,)M.A.)et)al)2012
m7G WDR4) Michaud,)J.)Et)al)2000
A2to2I)editing ADAT3 Alazami,)A.M.)et)al)2013
Familial)dysautonomia mcm5s2U IKBKAP Slaugenhauupt,)S.A.)and)Gusella,)J.F.)2002)Chen,)C.)et)al)2009
Amyotrophic)lateral)sclerosis mcm5s2U ELP3 Simpson,C.L.)et)al)2009
Rolandic)epilepsy mcm5s2U ELP4 Strug,)L.J.)Et)al)2009
Dubowitz2like)syndrome m5C NSUN2 Martinez,)F.J.)Et)al)2012
Cardiac Noonan2like)syndromed m5C NSUN2 Fahiminiya,)S.)et)al)2013
Respiratory Bronchial)asthma mcm5s2U IKBKAP Takeoka,)S.)et)al)2001
Cancer Skin,)breast,)and)colorectal m5C NSUN2 Frye,)M.)and)Watt,)F.M.)2006)))))))))))))))Vachon,)C.M.)et)al)2007
Breast wybutosine TRMT12 Rodriguez,)V.)et)al)2007
m5U TRMT2A Barlett,)J.M.)et)al)2010
Colorectal m1G HRG9MTD2) Berg,)M.)et)al)2010
Urothelial mcm5U HABH8)(HALKBH8) Shimada,)K.)Et)al)2009
Breast,)bladder,)colorectal,)
cervix,)testicular mcm5U HTRM9L Bergley,)U.et)al)2013
Epigenetic)cancer)treatment m5C DNMT2 Schaefer,)M.)et)al)2009
Metabolic Type)2)diabetes ms2t6A CDKAL1 Saxena,)R.)et)al)2007))))))))))))))))))))))))))))))))))))))Wei,)F.Y.)And)Tomizawa,)K.)2011
Mitochondrial=linked MELAS τm5U mt)tRNALeu(UAA)
Yasukawa,)T.)et)al)2000))))))))))))))))))))))))))))
Kirino,)Y.)Et)al)2005)))))))))))))))))))))))))))))))))))
Kirino,)Y.)Et)al)2006
MERRF τm5s2U mt)tRNALys(UUU) Yasukawa,)T.)et)al)2000
Infantile)liver)failure s2U MTU1)(TRMU) Zeharia,)A.)et)al)2009
Deafness)associated)with)
mutations)in)mitochondrial)
12S)ribosomal)RNA
s2U MTU1)(TRMU) Guan,)M.X.)Et)al2006
Table 1: summary of human diseases linked to tRNA modifying enzymes. Table adapted 
from Torres, A.G. et al 2014. 
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1.5 tRNA modifying enzymes in beta cell dysfunction and demise 
1.5.1  CDKAL1 
One of the tRNA modifying enzymes most characterized at the level of 
pancreatic beta cells is the Cdk5 regulatory associated protein 1 
(CDKAL1). Whole genome sequencing studies have identified several 
SNPs in CDKAL1 associated with impaired insulin secretion and type 2 
diabetes (T2D)50,51,52. CDKAL1 is a member of methylthio-transferase 
(MTTase) family characterized by the S-adenosyl-methionine (SAM) 
domain53 and catalyzes the modification of N6-threonyl carbamoyl 
adenosine (t6A) in 2-methylthio-N6-threonyl carbamoyl adenosine 
(ms2t6A) at position 37 of tRNALys(UUU) in mammals54. Wei at al. elegantly 
clarified the role of CDKAL1 using in vitro and in vivo techniques. They 
found that the protein localizes in the ER (Figure 7 A) and demonstrated 
that the 2-methyl-thio modification is necessary to prevent the misreading 
and frame shifting of tRNALys(UUU)’s cognate codons during protein 
translation. The role of CDKAL1 in the development of type 2 diabetes was 
studied in beta cell specific Cdka1-deficient mice. Beta cell knockout mice 
show decreased level of C-peptide, accumulation of proinsulin in C-peptide 
negative granules and impaired glucose stimulated insulin secretion. The 
transcription of insulin gene produces preproinsulin that is transported to 
the endoplasmic reticulum through the interaction of signal-recognition 
molecules with the 24 aa signal peptide. In the ER the signal peptide is 
cleaved and proinsulin is folded and transferred to the Golgi where is 
charge in secretory granules. In the granules proinsulin is processed 
through the cleavage and excision of the C-peptide and the binding of the B 
and A chains55. One specific lysine residue is located in the cleavage site 
between the C-peptide and the A-chain and is important for the processing 
of proinsulin. Misreading of lysine residues due to the absence of CDKAL1 
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can lead to inappropriate proinsulin processing. It was shown that in 
CDKAL1 knockout islets the incorporation of lysine residues in proinsulin in 
significantly decreased (Figure 7 B)54. Furthermore the absence of 
CDKAL1 induces the expression of ER stress related genes, probably 
because of accumulation of misfolded proteins in the ER56, and this can 
lead to increased high fat diet susceptibility as was observed in islets-
specific knockout mice54.  
  
Figure 7: Key results published in Wei et al. 2011. A): the colocalization of CDKAL1 with 
Bip (ER marker) was identified by overexpression of the protein fused to GFP in HEK293 
cells. Results show a significant decrease of relative incorporation of 14C-lysine to 3H-
lysine in immunoprecipitated pro-insulin (B), a decrease of pro-insulin synthesis with high 
glucose concentration (C) in islets of beta cell CDKAL1 knockout mice compared to Flox 
controls mice and decreased plasma insulin in knockout mice (D).  
A 
B C D 
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1.5.2  TRMT10A 
tRNA Methyltransferase 10 Homolog A (TRMT10A) is a protein containing 
a (guanine-9)methyltransferase domain and is an homolog of the yeast 
protein TRM10 that modifies tRNAs substrates at the level of G9 residues. 
Igoillo-Esteve et al in 2013 identified a homozygous non sense mutation in 
TRMT10A gene that leads to young onset diabetes and primary 
microcephaly in siblings from a consanguineous family. The nucleotide 
variant G379A in TRMT10A gene leads to the insertion of a stop codon at 
position 127 of the encoded polypeptide (Arg127Stop) and consequently to 
the absence of the protein in lymphoblasts from patients and reduced 
mRNA level; this suggests a mechanism of nonsense-mediated mRNA 
decay. TRMT10A is ubiquitously expressed in rat tissues but is more 
abundant in pancreas and brain at both mRNA and protein level (Figure 8 
A B). The protein localizes predominantly in the nucleolus of beta and non 
beta cells of rat and human pancreatic islets (Figure 8 C-D)57. In vitro 
studies showed that TRMT10A knockdown induces apoptosis in rat beta 
cells and dispersed human islets in basal condition and sensitizes the cells 
to free fatty acids and ER stress mediated apoptosis, while doesn’t affect 
glucose stimulated insulin secretion. Another recent report described the 
identification of the homozygous TRMT10A mutation Gly206Arg associated 
with abnormalities in glucose homeostasis, short stature and 
microcephaly58. The mutation was found in three siblings of a 
consanguineous family. The altered glucose homeostasis was initially 
manifesting with ketotic and non-ketotic hypoglycaemia with transition to 
diabetes in adolescence, maybe because of accelerated beta cell 
apoptosis. The Gly206Arg mutated protein is still synthesized but shows 
defects in the methylation of tRNA substrates in vitro (<0.1% compared to 
wild type enzyme) even if the binding to tRNA molecules is not altered. 
Moreover Zung et al reported a case of homozygous deletion of TRMT10A 
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gene in a patient with diabetes mellitus, delayed puberty and intellectual 
disability59.  All these findings suggest that TRMT10A plays a crucial role in 
beta cell function and survival, but the mechanism by which it regulates 
cellular responses is still unclear. Furthermore the role of TRMT10A as 
tRNA modifying enzyme in human in vivo remains to be described. 
 
  
A B 
C 
D 
Figure 8: Results published by Igoillo-Esteve et al (2013) relative to the expression of 
TRMT10A in rat tissues (A-B): the expression is enriched in pancreatic islets (mRNA and 
protein level) and brain (protein level). Immunofluorescence microscopy was used to 
evaluate the expression of TRMT10A GFP-fused protein in beta and non beta cells in rat 
(C) and human islets (D).  
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2 AIM 
tRNA modifying enzymes have been shown to be crucial to ensure the 
stability and the correct function of tRNAs. Furthermore several evidences 
have recently highlighted the role of tRNAs in cell signaling, linking these 
molecules with the activation of stress response pathways. Basing on these 
observations it became clear the importance of studying tRNA modifying 
enzymes role in pancreatic beta cells that are particularly sensitive to 
environmental stress.  
The study of monogenic diseases associated with beta cells dysfunction 
and demise is a good model for the investigation of essential cellular 
mechanisms. With this purpose I managed a list of candidate genes of 
congenital hyperinsulinism derived from a whole exome sequencing study. 
The objectives of this part of my project are: 
Ø Identifying new candidate genes for Congenital hyperinsulinism 
using bioinformatics tools; 
Ø Studying the consequences of the variant S561F of CDKAL1, a 
tRNA methyl-thio transferase, on the protein in a model of beta 
cell; 
Ø Evaluating the S561F CDKAL1 impact on beta cell function. 
The second part of my project regards the characterization of the tRNA 
modifying enzyme TRMT10A in beta cells. TRMT10A deficiency has been 
linked to the development of microcephaly and young onset diabetes. My 
work in this context aimed to investigate  
Ø The role of TRMT10A in tRNA modification, stability and charging 
in human cells, 
Ø The consequences of TRMT10A deficiency on modulation of 
apoptosis pathways in beta cells; 
Ø The effect of TRMT10A deficiency on ER stress-induce apoptosis 
in beta cells; 
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3 MATERIALS AND METHODS 
3.1 Plasmids  
Expression plasmid for Human CDKAL1 with HA (hemagglutinin) tag was 
kindly provided by Dr. Michele Solimena (Universitatsklinikum Carl Gustav 
Carus an der Technischen Universitat Dresden). The single nucleotide 
variant C-1682-T found in CHI patients was introduced in the human ORF 
with QuickChangeII XL site-directed kit (Agilent Technologies®) using the 
mutagenesis primers: 
CT antisense    5’-CAAGCCCACGAACATCCTCAGCGCACAGTC-3’ 
CT sense          5’-GACTGTGCGCTGAGGATGTTCGTGGGCTTG-3’ 
3.2  Cell culture 
Rat INS-1E cells (kindly provided by Prof. Wolheim, Geneva) were cultured 
in RPMI-1640 GlutaMAX-I medium (Invitrogen) supplemented with 5% FBS 
as previously described60. The EndoC-βH1 human beta cell line was 
cultured in low glucose DMEM (Invitrogen) in plates coated with Matrigel 
100 µg/ml and fibronectin 2 µg/ml as described61. Human lymphoblasts 
from control individuals, two patients and one heterozygous carrier of the 
mutation were cultured in RPMI 1640 medium supplemented with 20% 
FBS, 100 mU/ml penicillin and 100 mU/ml streptomycin.  
Establishment of CDKAL1 overexpressing INS-1E clones: INS-1E cells 
were transfected with lipofectamine 2000 (Invitrogen) in dishes of 6 cm 
diameter. About 16 hours post transfection the medium was supplemented 
with 0.5 g/L of neomycin. Medium containing neomycin was changed every 
day for 7 days. Cells were then trypsinized and diluted 3 cells/20µl (150 
cells/ml). 20 µl were distributed to each well of the 96 well plates. Cells 
were cultured in the wells for about 2 weeks until colonies were visible.  
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RNA interfence: Cells were transfected using Lipofectamine RNAiMAX 
(Invitrogen). The siRNA-lipid complex was formed in Opti-mem medium 
(Invitrogen) with an incubation of 20 min at room temperature. The final 
concentration of the siRNA in the transfection medium was 30nM. 
Transfection conditions are summarized in table. The transfection was 
induced overnight and all the experiments were performed after 48 hours 
from the transfection. Cells were transfected using different siRNAs: control 
siRNA (Qiagen), three different siRNAs targeting rat TRMT10A 
(siTRMT10A #B, #C and #D), two siRNAs targeting human TRMT10A 
(siTRMT10A #1 and #3), siRNA specific for rat Bim and siRNA for human 
Bim (siBim). The control siRNA is characterized by a random sequence 
that doesn’t interfere with the expression of any gene. The sequences of 
siRNAs used are reported in table 3.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Molecule 
transfected 
Lipofectamine 
transfection agent Plate 
Transfection 
agent volume per 
well (µl) 
Final volume 
(µl) 
siRNA RNAiMAX 24 wells 1.0 500 
siRNA RNAiMAX 96 wells 0.2 100 
Table 2: Transfection conditions used in INS-1E and EndoC-βH1 cells. 
Table 3: sequences of siRNAs used to silence the expression of different genes in rat INS-
1E or human EndoC-βH1 cells. 
Species Gene name siRNA name Sequence 
Rat Bim siBim 5’#GAGUUCAAUGAGACUUACACGAGGAU(
CCUCGUGUAAGUCUCAUUGAACUC#3’(
Rat TRMT10A  siTRMT10A #B 5’#CCUAUGUGAUUGGAGGGUUAGUGGAU(
CCACUAACCCUCCAAUCACAUAGG#3’(
siTRMT10A #C 5’#CACGUUUAAGCAAGCUCCAGUUAUAUA(
ACUGGAUGCUUGCUUAAACGUG#3’((
siTRMT10A #D 5’#UGCAGAGGCCCAGCCAAUAUCUAAA#3’(
Human Bim siBim 5’#CACGAAUGGUUAUCUUACGACUGUU#3’(
Human TRMT10A siTRMT10A #1 5’#CAGAGCACUAUAGUGAACUCAUAAAUUUA(
UGAGUUCACUAUAGUGCUCUG#3’((
siTRMT10A #3 5’#CCAUCACAAGGGACUCACAUAAUAAAAUUU(
AUAUGUGAGUCCCUUGUGAUGG#3’(
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Cells treatment: Palmitate (sodium salt, Sigma) was dissolved in 90% 
ethanol and diluted 1:100 to a final concentration of 0.5 mM. The chemical 
ER stressor thapsigargin, a SERCA pump blocker, was used at the 
concentration 1 µM. Combination of cytokines was used at the following 
concentrations: recombinant human IL-1β (R&D Systems, Abingdon, UK) 
50 U/ml, human IFN-γ (Peprotech, London, UK) 1000 U/ml. For all 
treatments the control condition contained the same dilution of vehicle.  
3.3 Cell viability 
The evaluation of cell death was performed staining the cells with DNA 
dyes Hoechst 342 (20 mg/ml) and propidium iodide (10 mg/ml) (HO/PI). 
Apoptotic cells, due to a change in membrane permeability, show an 
increased up-take of the dye Hoechst 342 compared to live cells. 
Propidium iodide is added to discriminate late apoptotic or necrotic cells, 
which have lost membrane integrity that leads the entrance of the dye. Live 
or early apoptotic cells have intact membranes that cannot be crossed by 
the dye. After 15 min incubation at 37°C with the staining solution the cell 
death was evaluated using inverted fluorescence microscopy. Cell death 
was determined in at least 600 cells in each experimental condition by at 
least two observers.  
3.4 Western Blot 
Cells were washed once with cold PBS, lysed and collected in Laemmli 
buffer (60 mmol/l Tris pH 6.8, 10% Glycerol, 1% SDS, 0.001% blue 
Bromophenol and 5% β-mercaptoethanol). Cell lysates were resolved in 
SDS-PAGE gels and transferred to nitrocellulose membranes. 
Immunoblotting was performed using specific primary antibodies for the 
protein of interest (Table 4). After incubation with secondary antibodies 
horseradish peroxidase (HRP) conjugated, the membranes were detected 
adding the chemiluminescent substrate Luminol with the ChemiDoc system 
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(Biorad). Antibodies used are reported in table. The quantification of 
detected bands was performed with ImageJ software.  
 
 
 
 
 
 
 
 
 
3.5 RNA extraction 
PolyA+-RNA was isolated from INS-1E and EndoC-βH1 cells using oligo-dT 
25-coated polystyrene Dynabeads (DYNAL Oslo, Norway). cDNA was 
prepared with the GeneAmp RNA PCR Kit (Perkin-Elmer, Norwalk 
Conn,USA). The cDNA was used to perform Real Time PCR. For northern 
blot experiments, total RNA from lymphoblast cells was extracted in acid 
condition to preserve the aminoacylation of tRNA molecules. The cells 
were pelleted at 4°C, resuspended in 0.3 ml of 0.3 M sodium acetate (pH 
4.5) and 10 mM EDTA, and lysed in volume of phenol equilibrated with the 
same buffer. Cells were vortexed three times for periods of 30, 60, and 60 
seconds with 60 seconds intervals between each step. Samples were then 
centrifuged for 10-15 min and the aqueous phase was transferred to new 
tubes containing 0.3 ml of phenol, vortexed for 60 seconds, and centrifuged 
for 10 min. The aqueous layer was transferred to new tubes and the RNA 
Antibody Specificity Ref Number Company Band Size (KDa) 
Bim Rat, Human 2819 Cell Signaling 23 (EL), 15 (L), 12 (S) 
Cleaved Caspase 9 Rat 9507 Cell Signaling 38 
Cleaved Caspase 9  Human 7237 Cell Signaling 37 
Phospho-Bad 
(Ser136) 
Rat, Human 4366 Cell Signaling 
 
23 
Bad Rat, Human 9239 Cell Signaling 23 
Table 4: List of antibodies used for western blot experiments. WB membranes were 
incubated with antibodies diluted in TBS-Tween 5% BSA. 
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was precipitated with 2.5 volumes of ethanol, and incubated on ice for 1-2 
hours. Total nucleic acids were recovered by centrifugation for 15 min. The 
pellet was dissolved in 60	   µl of 0.3 M sodium acetate (pH 4.5). Nucleic 
acids were precipitated again with 2.5 volumes of ethanol, incubated on ice 
for 2-3 hours, and recovered by centrifugation for 15 min. The pellet was 
dissolved in 20 µl of 10 mM sodium acetate (pH 4.5) and 1 mM EDTA. An 
aliquot was used to measure absorbance at 260 nm after dilution 1:1 in 
100mM Tris-HCl pH 7.0. Another aliquot was used for the alkali treatment 
in order to induce the complete de-aminoacylation of tRNA. These samples 
were used as control to detect the position of de-aminoacylated tRNAs in 
the electrophoretic gels. 50 µg of total RNA were diluted in water to 40 µl 
and treated with Add 5 µl of 10 mM EDTA (pH 8.0) and 5 µl of 1 M Tris-HCl 
(pH 8.9) at 37°C for 60 min. After the incubation sodium acetate 3 M (pH 
5.0) was added to a final concentration of 0.3M, RNA was precipitated in 
2.5 volumes of ice-cold 95%, incubated on ice for 10 min and recovered by 
centrifugation at 13.000xg for 10 min at 4°C. Pellet was washed once with 
70% ethanol and dissolved in 10-20 µl of 10 mM sodium acetate (pH 4.5) 
and 1 mM EDTA. For primer extension assay total RNA from lymphoblasts 
was extracted using a variation of the RNAesay kit (Qiagen) protocol. The 
pellet derived from centrifugation of lymphoblast cells was passed through 
QiAShered column that allows the fragmentation of long nucleic acid into 
smaller fragments. Columns were centrifuged at 12000 rpm for 2 min and 
the homogenates were incubated at room temperature for 5 min. Samples 
were mixed with 140 µl of chloroform, incubated 23 min at room 
temperature and the centrifuged. The aqueous phase was transferred to a 
new tube and RNA was precipitated adding 70% ethanol. Samples were 
passed through RNeasy Mini spin column that binds long RNAs (longer 
than 200bp), while the flow-through contains the short RNAs; column was 
washed and the long RNAs were eluted with RNAse-free water. Short 
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RNAs contained in the flow-through were precipitated adding 100% ethanol 
and then passed through RNeasy MinElute column that binds shorter 
molecules of RNA. Column was washed and then short RNAs were eluted 
with RNAse-free water and used for the purification of tRNAs. RNA 
samples were quantified by nanodrop after dilution 1:1 in 100 mM Tris-HCl 
pH 7.0. 
3.6 tRNA purification 
tRNA purification protocol was set up adapting the method already 
described in literature62. Column of matrix for the purification were prepared 
placing Nucleobond XTRA resin (MACHEREY-NAGEL) in Pasteur pipettes 
equipped with a filter. The matrix was equilibrated with equilibration buffer 
(50 mM Tris-H3PO4 pH 6.3, 15% ethanol, 300 mM KCl). Columns were 
washed once with equilibration buffer and tRNAs were eluted with elution 
buffer (100 mM Tris-H3PO4 pH 6.3, 15% Ethanol, 650 mM KCl). 20 
fractions were collected and the absorbance at 260 nm was monitored. The 
fractions corresponding to the peak of the absorbance were pooled and the 
tRNAs were precipitated incubating the samples with 0,7 volumes of 
isopropanol for 1 hour at 4°C. After centrifugation at 20000 rcf for 30 min at 
4°C the pellet was washed once in 70% ethanol and then dried and 
resuspended in RNA-free water. 
3.7 Quantitative real time PCR 
Real-time PCR was performed using FastStart SYBR Green on the 
LightCycler (Roche Diagnostics) or Rotor-Gene SyBR Green on a Rotor-
Gene Q cycler (Qiagen). Suitable primers were used to perform a 
conventional PCR for the preparation of the standards. Using the standard 
curve approach, gene expression was calculated as copies/ml and the 
values were normalized with the expression of the reference genes 
GAPDH and/or b-actin, which resulted to be not modified by the 
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experimental conditions. The sequences of primers used for Real Time 
PCR are provided in Table 5. 
 	  	  	  	  	  	  	  	  	  	  	  	  	  
 	  	  	  
3.8 Radio labeling of primers and RNA probes 
Oligonucleotide primers used for primer extension assay and RNA probes 
used for northern blot experiments were 5'-end-labeled using [γ-32P]ATP 
and T4 polynucleotide kinase. The labeling reaction was performed mixing 
20 pmol oligonucleotide, 0,15 mCi [γ-32P]ATP, 2 µl 10X reaction buffer, 
10U T4 polynucleotide kinase, DEPC-treated water up to 20 µl. Samples 
were incubated at 37°C and after 1 hour the reaction was stopped by 
adding EDTA to 1 mM, pH 8.0 and heating at 95°C for 2 minutes. RNA 
primers and probes sequences are reported in table 6 and table 7.  
Species Gene name Primer forward Primer Reverse 
Rat Bad 5’-CCAATAACAGTCATCATGGAG-3’  5’-GTCCTCGAAAAGGGCTAAG-3’  
Rat Bim 5’-AGAGATACGGATCGCACAGG-3’  5’-GTCTTCCGCCTCTCGGTAAT-3’  
Rat Bim S 5’-CAGAATCGCAAGCTTCCATA-3’ 5’-GTCTTCCGCCTCTCGGTAAT-3’ 
Rat DP5  5’-GCCGTGGTGTTACTTGGACT-3’  5’-GATTGTGCCAGAGCTTCACA-3’  
Rat Puma 5’-AGTGCGCCTTCACTTTGG-3’  5’-CAGGAGGCTAGTGGTCAGGT-3’  
Rat TRMT10A  5’-ATGACTTGATGGTGTTAAAG-3’  5’-ATCCATGTTCTTCTTCAGTTG-3’  
Rat GAPDH 5’-AGTTCAACGGCACAGTCAAG-3’  5’-TACTCAGCACCAGCATCACC-3’  
Human Bim 5’-TTCTTGCAGCCACCCTGC-3’ 5’-CTTGCGTTTCTCAGTCCGA-3’ 
Human Bim S 5’-GAGCCACAAGCTTCCATGAG-3’ 5’-TAACCATTCGTGGGTGGTCT-3’ 
Human TRMT10A 5’-ATGTTGTTCATAGCACCCTTC-3’  5’-ATGTTCTTTTTCAGCTGGCCT-3’ 
Human β-Actin 5’-CTGTACGCCAACACAGTGCT-3’  5’-GCTCAGGAGGAGCAATGATC-3’  
Table 5: Sequences of primers used for quantitative Real Time PCR. 
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3.9 Primer extension assay  
Primer extension assay previously described63 was used to study the role 
of TRMT10A in methylation of G9 (m1G9) residues of different tRNA 
species. Purified tRNAs are retrotranscribed using 32P-radiolabeled primers 
targeting specific tRNAs. The presence of m1G9 modification stops the 
reverse transcription due to the N-1 methyl group that prevents the 
formation of base pair necessary to continue the extension and thus 
generating shorter amplicons. The annealing of specific primers was 
performed mixing 50 mM Tris-HCl pH 8.3, 30 mM NaCl, 10 mM DTT, 1 
tRNA molecule Probe sequence 
tRNA-Histidine 5’-CGAACCGAGGUUGCUGCGGCCACAACGCAGA 
GUACUAACCACUAUACGAUCACGGC-3’ 
tRNA-Methionine 5’-CGAUCCAUCGACCUCUGGGUUAUGGGCCCAG 
CACGCUUCCGCUGCGCCACUCUGC-3’ 
tRNA-Glutamine 5’- CUCGGAUCGCUGGAUUCAAAGUCCAGAGUGC 
UAACCAUUACAC -3’ 
5s-rRNA 5’-GACCCUGCUUAGCUUCCGAGAUCAGACGAG-3’ 
Table 7: RNA oligonucleotide probes used for northern blot experiments. 
tRNA molecule Primer 
tRNA-Histidine 5’#TGCGGCCACAACGCAGAGTA#3’)
tRNA-Methionine 5’#TTCTGGGTTATGGGCCCAGC#3’)
tRNA-Glutamine 5’#GCTGGATTCAAAGTCCAGA#3’)
tRNA-Glycine 5’#CCTCCCGCGTGGCAGGCGAG#3’)
tRNA-Asparagine 5’#TTTCGGTTAACAGCCGAACG#3’)
Table 6: RNA oligonucleotides used for primer extension assay targeting different tRNAs. 
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pmol primer and 0.5 µg of purified tRNA. The mix was heated at 95°C for 3 
minutes and then slowly cooled to 37°C. Annealed tRNA/primers were 
used for reverse transcription reaction. 2 µl of annealing reaction were 
added to 5 µl reaction mix containing 0.7 µl MgCl2, 0.7 µl dNTPs, 0.7 µl 
10X buffer, 0.35 µl MuLV reverse transcriptase, 0.35 µl RNase inhibitor and 
2.2 µl water. Samples were incubated 5 minutes at room temperature and 
then at 37°C for 1 hour. The reaction was stopped adding 7 µl of loading 
buffer containing 90% formamide, 18.6% EDTA, 0.1% xylene cyanol, 0.1% 
bromophenol blue and 10% glycerol. The amplicons are separated in 15% 
polyacrylamide gel containing 4 M urea. Gel was pre-run in 1X TBE buffer  
(0.09 M Tris base, 0.09 M boric acid and 2 mM EDTA) at 200 V for 30 
minutes and before loading the samples the wells were cleaned from 
excess of urea. After loading the samples, gel was run at 120 V for 30 
minutes and then at 150 V for 1 hour. Gel was fixed in 1X TBE 10% 
methanol and 10% ethanol. Signal was detected by autoradiography. 
3.10  Northern Blot 
Total RNA samples extracted in acid condition were resolved on acid-urea 
gels. Samples were diluted 1:1 in acid loading buffer containing 0.1 M 
sodium acetate (pH 5.0), 8 M urea, 0.05% bromophenol blue, and 0.05% 
xylene cyanol and loaded into 6.5% polyacrylamide gel (19:1 acrylamide: 
bisacrylamide) containing 8 M urea in 0.1 M sodium acetate buffer (pH 5.0). 
Electrophoresis was performed at 80 V (-12 V/cm) was performed in a cold 
room until the bromophenol blue dye reached the bottom of the gel. The 
portion of the gel between the xylene cyanol and bromophenol blue dyes, 
contains the tRNAs of interest. Samples were blotted onto a positively 
charged nylon membrane (ThermoFisher) using at 20 V overnight with Tris 
Borate-EDTA buffer (TBE) buffer 0,5X as transfer buffer. Membrane was 
crosslinked with UV light for 10 minutes. Membranes were pre-hybridized 
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with North2South hybridization buffer (ThermoFisher) for 30 min and then 
hybridized overnight with radiolabeled RNA probes at 65°C shaking. The 
signal of radiolabeled probes was detected by autoradiography.  
3.11 Autoradiography 
Gels from primer extension assay and membranes from northern blot were 
placed in intensifying screens TranScreen HE (Kodak) that convert most of 
the penetrating radiation energy to photons providing maximum sensitivity. 
The radioactive signals were detected using Amersham Hyperfilm MP (GE 
Healthcare Limited, UK), placed in a cassette and incubated at -80°C. 
Before the detection the cassette was defrost. Autoradiography was 
processed manually using Carestream developer and fixator solutions 
(Kodak). 
3.12 Bioinformatics tools 
ExPASy portal (http://expasy.org) was used to access different databases 
to obtain information about function and domains of proteins of interest. 
Modomics database (http://modomics.genesilico.pl) was used to investigate 
the nucleotide sequences of different tRNAs and the specific nucleotide 
modifications.  
The list of genes derived from whole exome sequencing of congenital 
hyperinsulinism was analyzed using the candidate gene prioritization tool 
ToppGene (https://toppgene.cchmc.org/prioritization.jsp). ToppGene 
produces two outputs: the first is the functional profile of a training set of 
genes, enriched with different annotation categories (training set output)64. 
The training set is a reference list of genes, such as known causative 
genes of a disease. The second output represents the level of similarity 
between the test set genes and the training set. The tool produces a 
similarity score for each functional category and an average of scores, 
obtained by meta-analysis; genes are ranked for statistical significance of 
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scores: p values are calculated using a Bonferroni statistical test. Genes 
used as training set and as test set are reported in table 8. 
 
 
 
 
 
 
 
 
 
 
 
3.13 Statistics 
Data are presented as means ± SEM. Non-normally distributed variables 
were log-transformed before statistical testing. Comparisons between 
groups were made by ANOVA followed by two-sided Student’s paired t test 
with Bonferroni correction for multiple comparisons. A p-value <0.05 was 
considered statistically significant.  
TRAINING SET LIST TEST SET LIST 
ABCC8, KCNJ11, GLUD1, GCK, HADH, 
SLC16A1, HNF4A, HNF1A, UCP2, 
ABCC8 
KCNH6, GNAS, ACACB, NOTCH2, 
SLC37A3, CSMD1,, RYR3, TRPV3, 
TRPC5, CAMK2D, PIK3R3, CDKAL1, 
SCN8A, KCNJ10, PDE4C, NOS2, 
SLC24A6, SULF1, TLL1, CACNA1A, PC 
Table 8: Gene lists used for candidate gene prioritization. The training set is the list of 
known causative genes of congenital hyperisnulinism, the test set is the list of genes derived 
from whole exome sequencing of congenital hyperinsulinism patients not mutated in known 
causative genes. 
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4 RESULTS 
4.1 S561F CDKAL1 variant  
4.1.1 Identification and in silico study of the variant  
Prioritization tools can be useful for searching unknown genes causing or 
associated with a disease, basing on the hypothesis that similar 
phenotypes are caused by similar genes. I used the list of congenital 
hyperinsulinism causative genes as training set and the list of genes 
derived from the previous WES study as test set. I considered the output 
relative to three functional categories: disease, human and mouse 
phenotype. The output of prioritization analysis shows that some genes 
significantly correlate with phenotypes associated to CHI causative genes, 
among these CDKAL1 ranked in the top positions of the three functional 
categories (Figure 9 A). The nucleotide variant identified by WES is the 
c1682t that results in the amino acid change S561F. CDKAL1 protein 
sequence consists in 579 amino acid residues; the Methyl-thiotransferase 
catalytic domain (MTTAse) is located at the N-terminus (64-172aa); the 
core of the protein is a radical SAM domain, containing a cysteine motif 
CxxxCxxC that binds a [4Fe-4S] cluster, used to cleave S-
adenosylmethionine (SAM) to generate methionine and a 5'-deoxyadenosyl 
radical. The TRAM domain predicted to bind tRNA molecules localises 
between the 431 and the 493 residues. CDKAL1 is a tail-anchored protein 
inserted in the membrane of the ER through the C-terminus hydrophobic 
domain56. The S561F variant localises in the hydrophobic transmembrane 
domain comprised between the positions 556-578. I used the HeliQuest 
(http://heliquest.ipmc.cnrs.fr) tool from ExPASy portal to analyse the 
interaction of the α-helix residues in the wild type and mutated sequence. 
The substitution of a serine with a phenylalanine, more hydrophobic 
residues, leads to an increase of hydrophobicity of the transmembrane 
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domain and decrease of the hydrophobic moment that quantifies the 
amphiphilicity of a helix (Figure 9 C). These changes could affect the 
stability of the protein in the membrane and consequently the turnover and 
the localization.  
  
Figure 9: A) Top position of the rank derived from candidate gene prioritization tool of ToppGene 
portal; B) Prediction of conserved CDKAL1 domains; C) prediction of α-helix organization and 
characteristics in wild type and S561F CDKAL1. 
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4.1.2 Overexpression of CDKAL1 in INS1E cells 
In order to perform functional studies in beta cells I obtained stably 
transfected INS1-E clones expressing the human ORF of CDKAL1 fused to 
a HA-tag. I selected different clones expressing the wild type and the 
S561F CDKAL1. Since the S561F mutation affects the C-terminal trans-
membrane domain the localization of CDKAL1 was monitored by indirect 
immunofluorescence using a commercial anti-HA antibody and confocal 
analysis. As reported, wild type CDKAL1 localized in a reticular 
compartment, diffused in the cell cytoplasm. The genetic variant S561F 
similarly was confined in a reticular compartment, although its localization 
was enriched in enlarged vesicular structures (Figure 10). 
  
 
  
Figure 10: Immunofluorescence staining of wild type (WT3) and mutant CDKAL1 (MUT3 and 
MUT7) in stably transfected INS-1E cells. Blue: DAPI labelled nuclei; green: CDKAL1 with HA 
tag is visualized with Alexa Fluor® 488 dye staining.  
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To investigate if the S561F CDKAL1 variant could affect beta cells function, 
I evaluated the insulin content and release in INS1E clones. As it was 
expected the overexpression of wild type CDKAL1 leads to an increase of 
insulin content; the overexpression of the variant S561F abolishes the 
increase of insulin content. On the other hand, the release of insulin in 
basal glucose condition is significantly increased in the mutated clones 
(Figure 11)  
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Figure 11: Quantification of insulin content (left) and release (right) in basal conditions 
(11mM glucose) in INS-1E non-transfected and overexpressing wilt type (wt) and mutated 
(S561F clone 1 and 2) CDKAL1. Data expressed as means ± SEM * p<0.05 
	   	  48	  
4.2 TRMT10A deficiency  
4.2.1 TRMT10A modifies tRNAGLN and tRNAiMeth in human cells 
The G379A variant of TRMT10A leads to the complete absence of the 
protein in patients affected by microcephaly and young onset diabetes. 
Different techniques were used to determine the function of TRMT10A in 
human cells and to understand the consequences of the deficiency of the 
protein. It was shown previously that TRMT10A is involved in the 
methylation of guanine residues in human cells (data non published): total 
RNA was extracted from lymphoblast cells of patients and control subjects 
and used for a mass spectrometry analysis of nucleotide modifications. The 
methylation of guanine residues in total RNA resulted to be decreased in 
lymphoblasts derived from two patients compared to the controls. This 
observation suggests that TRMT10A can be responsible of the methylation 
of guanine residues of tRNAs in vivo in human. To further investigate the 
role of TRMT10A, tRNA molecules characterized by a guanine residue in 
position 9 were identified using Modomics database 
(http://modomics.genesilico.pl). The tRNAs specific for glycine (Gly), 
glutamine (Gln), initiator methionine (iMeth) and asparagine (Asp) have a 
G9 residue and are potential substrates of TRMT10A. The primer extension 
assay was used to identify tRNA molecules modified by TRMT10A in vivo. 
tRNA faction was purified from total RNA samples derived from 
lymphoblasts of one patient (PA 1), one heterozygous carrier (HZ) and 
control subjects (CT1, CT2 and CT3). The sequence of the different tRNAs 
was amplified using specific 32P-radiolabeled primers; the products of 
amplification were resolved in urea-polyacrilamide gel and detected by 
autoradiography; the presence of the methylation in position 9 causes the 
block of the amplification that will produce amplicons of 35 base pairs. The 
absence of the modification allows the complete amplification of the tRNA 
	   	  49	  
sequence producing bigger bands (38bp). tRNAGln and tRNAiMeth resulted to 
be methylated at the level of G9 residue in lymphoblasts derived from 
control subjects but not in lymphoblasts from the patient (Figure 12). The 
G9 residue of tRNAAsp and tRNAGly is methylated in all the samples 
suggesting that the methylation of these tRNAs is not mediated by 
TRMT10A. tRNAHis (specific for histidine) was used as negative control 
since it doesn’t present a guanine in position 9.  These results 
demonstrated that TRMT10A deficiency leads to the absence of 
methylation of G9 residues in tRNAGln and tRNAiMeth and that these tRNAs 
are specific substrates of the enzyme in vivo.  It’s known from literature that 
tRNA modifications can affect the maturation and the stability of the 
molecules. Also the amino-acylation can be modulated by post-
transcriptional modifications. Based on that I set up a northern blot 
technique in order to detect and quantify aminoacylated and 
deaminoacylated tRNAs. Radiolabeled probes were used to detect 
specifically tRNAGln and tRNAiMeth that were shown to be TRMT10A 
substrates, and tRNAHis as negative control. Total RNA from lymphoblasts 
was isolated under acid conditions to preserve aminoacylation. 
Aminoacylated tRNAs are heavier and run slower in the electrophoretic gel, 
and can be distinguished from deaminoacylated molecules that run faster. 
To confirm that extracted tRNAs were aminoaylated, part of the sample 
was treated with alkali pH that induces complete deaminoacylation. These 
alkali treatment samples were used as controls in electrophoretic gels. 
Preliminary results showed in Figure 13 suggest that in basal codition the 
absence of G9 methylation in tRNAGln and tRNAiMeth may decrease the 
abundance of these molecules without affecting the aminoacylation. 
Nevertheless these results need to be confirmed analyzing a second 
patient and more controls.  
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Figure 12: Identification of TRMT10A tRNA targets by primer extension assays. tRNAs 
purified from lymphoblasts from two controls (CT1-2), one heterozygous carrier (HZ) and 
one TRMT10A-deficient patient (PA 1) were reverse transcribed using radiolabelled primers. 
G9 methylation (m1G9) stops the reverse transcription generating short amplicons (*). In the 
absence of m1G9 the reverse transcription continues up to the 5’ end of the tRNA (red 
dotted lines) generating longer amplification products (#). TRMT10A deficiency only modified 
the amplification pattern of tRNAGLN (A) and tRNAiMeth (B) but not of tRNAAsp  (C) and 
tRNAGly (D). As expected, no difference in the amplification pattern of the C9-containing 
tRNAHis (E) was observed. In the figure are shown cloverleaf structures of tRNAs and the 
autoradiography of the amplification products. Black lines represent the oligonucleotides 
used as primers, blue lines represent the reverse transcribed fragment from the 3’ end of the 
primer to the G9.  
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4.2.2 TRMT10A deficiency induces apoptosis in beta cells through the 
activation of the intrinsic pathway of apoptosis 
In order to obtain a model of TRMT10A deficiency in beta cells, I induced 
the knockdown of the gene through RNA interference in two beta cell lines: 
INS-1E, derived from rat insulinoma, and EndoC-βH1, a human beta cell 
line. It was already shown that TRMT10A silencing induces apoptosis in 
INS-1E cells57; To study the molecular mechanism of TRMT10A deficiency-
Figure 13: RNA isolated from lymphoblasts from control subjects (CT1, CT2), one 
heterozygous carrier (HZ) and one patient (PA 1) was analyzed by northern blot. Aliquots of 
the same samples were treated with alkali pH to induce complete deaminoacylation.  
tRNAiMeth, tRNAGLN  and tRNAHis were detected by hybridization of northern blot membranes 
with specific radiolabeled probes. Ribosomal RNA 5s-rRNA was detected and used as 
loading control. Autoradiography of representative blots is shown on the left. 
Autoradiography films were scanned and bands were quantified by optical density analysis: 
results from quantification are plotted in histograms on the right. Data are expressed as 
mean ± SEM (n=1-5). 
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induced apoptosis I have silenced TRMT10A in INS-1E cells using three 
different siRNAs (siTRMT10A #B, #C and #D) and I confirmed the induction 
of apoptosis previously shown (Figure 14 A-B). Interestingly, TRMT10A 
knockdown in EndoC-βH1 cells using two different siRNAs (siTRMT10A-
#1, siTRMT10A-#3) also induced apoptosis (Figure 14 C-D). To evaluate 
which pathway of apoptosis was activated by TRTM10A deficiency I 
examined the acttivation of Caspase 9, a hallmark of the intrinsic pathway 
of apoptosis. TRMT10A knockdown increased Caspase 9 cleavage 
(measured by western blot) in INS1E and EndoC-βH1 (Figure 15) 
suggesting that the intrinsic pathway of apoptosis is activated.  
 
 	  
  
Figure 14: A) TRMT10A mRNA expression normalized to the reference gene GAPDH B) 
percentage of apoptosis in INS-1E transfected with control siRNA (siCT) and siRNAs 
targeting rat TRMT10A (siTRMT10A #B, #C and #D) C) TRMT10A mRNA expression in 
EndoC-βH1 normalized to reference gene β-actin D) percentage of apoptosis in INS-1E 
transfected with control siRNA (siCT) and siRNAs targeting humanTRMT10A (siTRMT10A 
#1 and #3). Data are expressed as mean ± SEM (n = 9–11). siCT vs siTRMT10A * p<0.05 
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4.2.3 The BH3-only activator Bim is the mediator of TRMT10A deficiency-
induced apoptosis 
I have previously shown that the intrinsic pathway of apoptosis is activated 
with TRMT10A deficiency. I wanted next to identify which are the mediators 
of the process. To pursue this objective I evaluated the expression of the 
pro-apoptotic BH3-only family members Bim, Bad, DP5 and PUMA at 
mRNA level in INS-1E cells after TRMT10A silencing. TRMT10A 
Figure 15: A) Quantification of cleaved Caspase 9 by western blot in INS-1E transfected 
with control siRNA and siRNAs targeting rat TRMT10A (siTRMT10A #B, #C and #D). B) 
Quantification of cleaved Caspase 9 in EndoC-βH1 transfected with control siRNA and 
siRNAs targeting human TRMT10A (siTRMT10A #1 and #3). Left panels: representative 
blots, right panels: optical density analysis. Quantification of cleaved Caspase 9 was 
corrected by the geometric mean of the expression of the reference proteins α-tubulin and 
β-actin (INS-1E) or by the expression of the reference protein GAPDH (EndoC-βH1) Data 
expressed as mean ± SEM (n = 4–7). siCT vs siTRMT10A * p<0.05 
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knockdown induces a significant mRNA increase of Bim and Bad but not of 
DP5 or PUMA (Figure 16 A-B-C-D) in INS-1E cells. Alternative splicing 
produces three splice variants of Bim: BimEL, BimL and BimS. The isoform 
BimS was shown to have the most pro-apoptotic potency65. Interestingly, 
this specific Bim isoform resulted to be induced by TRMT10A knockdown in 
INS-1E cells (Figure 16 E). The mRNA expression of pro-survival proteins 
Bcl-2 and Bcl-xL was not modulated by TRMT10A silencing (data not 
shown obtained in our lab). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The results derived from mRNA expression of BH3-only members 
suggested that the activator Bim and the sensitizer Bad could mediate the 
apoptosis induced by TRMT10A deficiency. To investigate this hypothesis I 
Figure 16: mRNA expression measured by real-time PCR of total Bim (A), Bad (B), DP5 
(C) and PUMA (D) BH3-only family members and Bim S isoform (E) in INS-1E cells 
transfected with control siRNA (siCT) or siRNAs targeting TRMT10A (siTRMT10A #C). Data 
are normalized to the expression of reference gene GAPDH, and are expressed as mean ± 
SEM (n = 4). siCT vs siTRMT10A * p<0.05 
0.0#
0.5#
1.0#
1.5#
2.0#
2.5#
!siCT! siTRMT10A!#C!
Bi
m
!/
!G
AP
DH
!
0.0#
0.5#
1.0#
1.5#
2.0#
!siCT! siTRMT10A!#C!
DP
5!
/!
GA
PD
H!
0.0#
0.5#
1.0#
1.5#
2.0#
!siCT! siTRMT10A!#C!
BA
D!
/!
GA
PD
H!
0.0#
0.5#
1.0#
1.5#
2.0#
!siCT! siTRMT10A!#C!
PU
M
A/
GA
PD
H!
A! B!
C! D!
*# *#
0.0#
0.5#
1.0#
1.5#
2.0#
2.5#
siCT% siTRMT10A%#C%
Bi
m
%S
%/
%G
AP
DH
%
*#
E%
	   	  55	  
checked the activation of Bim and Bad at protein level. Transcriptional 
modulation and alternative splicing regulate the pro-apoptotic function of 
Bim. I observed a significant increase of the most pro-apoptotic isoform 
BimS in TRMT10A knockdown-INS-1E cells, while the isoforms Bim L and 
Bim EL were not modulated (Figure 17 A). The pro-apoptotic action of Bad 
is controlled by phosphorylation; dephosphorylated Bad can bind and 
inactivate the pro-survival proteins Bcl-2 and Bcl-xL inducing Bax/Bak-
triggered apoptosis. Bad phosphorylation at Ser136 by Akt and at Ser112 
by PKA plays a critical role in blocking the dimerization of Bad and Bcl-xL, 
promoting cell survival. I didn’t detect any significant change in Bad 
phosphorylation at Ser136 site after TRMT10A silencing (Figure 17 B) and 
in previous experiment from my group the Ser112 phosphorylation was not 
modulated by TRMT10A knockdown (data not shown). This suggests that 
Bim and not Bad activation is the key event mediating TRMT10A silencing-
induced apoptosis. Interestingly, results showed that Bim mRNA 
expression was significantly induced by TRMT10A knockdown also in 
human beta cells (Figure 18 A). The isoform BimS showed a trend of 
increase at mRNA level (Figure 18 B), while was significantly induced at 
protein level (detected with western blot) after TRMT10A silencing (Figure 
18 C).   
Since TRMT10A deficiency induces apoptosis via Bim activation, the 
absence of Bim is expected to be protective against TRMT10A silencing-
induced apoptosis. I verified this hypothesis inducing a double knockdown 
of TRMT10A and Bim in INS-1E cells (Figure 19). Cells were transfected 
with control siRNA or TRMT10A-specific siRNAs (siTRMT10A #C-#D) 
alone or in combination with siRNA specific for Bim (siBim). Bim silencing 
significantly protected TRMT10A deficient rat (Figure 19 A) beta cells from 
apoptosis. 
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Figure 17: Expression of Bim S, L and EL isoforms (A) and Bad phosphorylation at Ser136 
(B), examined by western blot, in INS-1E cells transfected with control siRNA (siCT) or 
siRNA targeting TRMT10A (siTRMT10A #B, #C and #D). Representative blots are shown, 
bands were quantify by optical densitometry analysis. Data are normalized to the geometric 
mean of expression of reference proteins α-tubulin and β-actin (Bim S, L and EL) or to total 
Bad expression (Phospho-Bad), Data are expressed as mean ± SEM (n = 4–7). siCT vs 
siTRMT10A * p<0.05 
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Figure 18: mRNA expression of total Bim (A) and BimS isoform (B) examined by real-time 
PCR in EndoC-βH1 cells transfected with control siRNA (siCT) and siRNAs targeting 
TRMT10A (siTRMT10A #1 and #3). mRNA data were normalized to β-Actin reference gene 
expression. The expression of Bim isoforms (Bim S, L and EL) was analysed by western 
blot in EndoC-βH1 cells (C) transfected with control siRNA and siRNAs targeting TRMT10A 
(siTRMT10A #1 and #3). Representative blot is shown; bands were quantified by optical 
densitometry analysis and normalized to the GAPDH reference protein expression. Data 
expressed as mean ± SEM (n = 3-5). siCT vs siTRMT10A * p<0.05 
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The efficiency of the knockdown was verified at mRNA level by real-time 
PCR: the expression of both TRMT10A and Bim was decreased by 60 to 
70% after transfection with the specific siRNAs compared to the control 
condition (Figure 19 B-C). I have shown that Bim is induced after 
TRMT10A silencing also in human beta cells. To further confirm the role of 
Bim as mediator of TRMT10A deficiency-induced apoptosis in human beta 
cells, EndoC-βH1 cells were transfected with siRNAs targeting TRMT10A 
(siTRMT10A #1 and #3) in combination with siRNA specific for Bim (siBim). 
A significant protection against TRMT10A knockdown-induced apoptosis 
was observed in cells transfected with siTRMT10A #3, that is the siRNA 
that induces more apoptosis in basal conditions (Figure 20 A). The analysis 
of mRNA expression by real-time showed a very good silcencing of 
TRMT10A (from 60 to 80%), while just a 40% of decrease was observe for 
Bim mRNA (Figure 20 B-C). A positive control experiment to confirm the 
effectiveness of Bim knockdown in EndoC-βH1 cells was performed in 
parallel. It was previously shown that Bim silencing protects EndoC-βH1 
cells from cytokines induced apoptosis66. For the positive control cells were 
transfected with siRNA of control (siCT) and siRNA targeting Bim (siBim) 
and treated with cytokines (h-IFNγ and IL-1β) for 24 hours (Figure 20 D-E). 
Bim silcencing protects cells from cytokines-induced apoptosis as it was 
expected, indicating that human Bim siRNA was effectively working despite 
the low knockdown efficiency observed by real-time PCR.  
In conclusion it was confirmed that Bim is the mediator of TRMT10A 
deficiency-induced apoptosis. 
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Figure 19: INS-1E cells were transfected with control siRNA (siCT) or siRNAs targeting 
TRMT10A (siTRMT10A #C and #D) alone or in combination with siRNA targeting Bim 
(siBim). After 48 hours from transfection, apoptosis was evaluated with HO/PI staining 
(A). TRMT10A (B) and Bim (C) mRNA expression was examined by real-time PCR.  
Data of real-time are normalized to the expression of reference gene GAPDH. Data are 
expressed as mean ± SEM (n = 3–7). *, # p<0,05 
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Figure 20: EndoC-βH1 cells were transfected with control siRNA (siCT) or siRNAs 
targeting TRMT10A (siTRMT10A #1 and #3) alone or in combination with siRNA targeting 
Bim (siBim). After 48 hours from transfection, apoptosis was evaluated with HO/PI staining 
(A). TRMT10A (B) and Bim (C) mRNA expression was examined by real-time PCR. (D) 
EndoC-βH1 cells after 48 hours from transfection with control siRNA or siRNA targeting 
Bim (siBim) were treated with cytokines (cyto) for 24 hours. Apoptosis was evaluated. (D) 
and mRNA expression of Bim (E) was examined. Data of real-time are normalized to the 
expression of reference gene GAPDH. Data expressed as mean ± SEM (n = 3–7). Data are 
expressed as mean ± SEM (n = 3–7). *, # p<0,05 
0.0#
5.0#
10.0#
15.0#
20.0#
25.0#
30.0#
35.0#
CT# Cyto#24h#
%
#A
po
pt
os
is
#
siCT#
siBim#
0.0#
0.3#
0.5#
0.8#
1.0#
1.3#
CT# Cyto#24h#
Bi
m
#/
#A
c3
n#
siCT#
siBim#
EndoC3βH1#
*#
##
*# *#
0.0#
5.0#
10.0#
15.0#
20.0#
25.0#
30.0#
35.0#
CT# Cyto#24h#
%
#A
po
pt
os
is
#
siCT#
siBim#
0.0#
0.3#
0.5#
0.8#
1.0#
1.3#
CT# Cyto#24h#
Bi
m
#/
#A
c3
n#
siCT#
siBim#
EndoC3βH1#
*#
##
*# *#
0.0#
5.0#
10.0#
15.0#
20.0#
25.0#
30.0#
35.0#
CT# Cyto#24h#
%
#A
po
pt
os
is
#
siCT#
siBim#
0.0#
0.3#
0.5#
0.8#
.0#
1.3#
CT# Cyto#24h#
Bi
m
#/
#A
c3
n#
siCT#
#
EndoC3βH1#
*#
##
*# *#
	   	  61	  
4.2.4 TRMT10A deficiency sensitizes beta cells to free fatty acid and ER-
stress induced apoptosis 
It was previously shown that TRMT10A mRNA expression is induced by 
treatment with palmitate and the chemical ER stressor cyclopiazonic acid 
(CPA) in INS-1E cells57. CPA is an inhibitor of the sarco/endoplasmic 
reticulum Ca2+ ATPase (SERCA) and causes the depletion of calcium 
storage leading to ER stress. Furthermore the TRMT10A knockdown 
sensitizes INS-1E cells to palmitate, oleate and ER stress induced 
apoptosis (Figure 21)57. To investigate if the BH3-only protein Bim is also 
the mediator of this process, I evaluated whether Bim silencing protected 
TRMT10A deficient beta cells from palmitate treatment. Bim knockdown 
protected INS-1E cells from palmitate-induced apoptosis in control 
condition and after TRMT10A silencing (Figure 22). In EndoC-βH1 cells, 
TRMT10A mRNA expression was induced by 24 hours treatment with 
Thapsigargin (Figure 23 A). Thapsigargin is an inhibitor of the 
sarco/endoplasmic reticulum Ca2+ ATPase (SERCA) that induces ER 
stress with the same mechanism of CPA. TRMT10A silencing sensitizes 
human beta cells to thapsigargin-induced apoptosis (Figure 23 B). 
Interestingly, silencing Bim had a protective effect against the sensitization 
to ER stressors induced by TRMT10A deficiency in human beta cells 
(Figure 24).  
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Figure 21: Figure adapted from Igoillo-Esteve, M. et al 2013. TRMT10A mRNA expression 
and percentage of apoptosis in INS-1E cells exposed or not (CT) to oleate (OL), palmitate 
(PAL), 28 mM glucose (G28), and chemical ER stressors cyclopiazonic acid (CPA), 
tunicamycin (TU) or brefeldin (BR). mRNA expression data are normalized to the geometric 
mean of GAPDH, tubulin and OAZ1 mRNA expression. Data expressed as mean ± SEM 
(n = 4–11).  *,§ p<0.05 
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Figure 22: Percentage of apoptosis in INS-1E cells after transfection with control siRNA 
(siCT), siRNA targeting TRMT10A (siTRMT10A #C) alone or in combination with siRNA 
targeting Bim (siBim) in cells treated for 16 hours with palmitate (PAL). Data are 
expressed as mean ± SEM (n = 4-8). * p<0,05 vs siCT(CT), # p<0.05 vs siCT(PAL), £ 
p<0,05 vs siTRMT10A(PAL)  
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Figure 23: A) TRMT10A mRNA expression in control condition and after 24 hours 
thapsigargin treatment in EndoC-βH1 cells. Data are normalized to the expression of 
reference gene β-actin; B) Percentage of apoptosis in EndoC-βH1 cells transfected with 
control siRNA (siCT) or targeting TRMT10A (siTRMT10A #1) in control condition and 
after 24 hours thapsigargin treatment. Data are expressed as mean ± SEM (n = 5-9).      
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Figure 24: Percentage of apoptosis in EndoC-βH1 cells after transfection with control 
siRNA (siCT), siRNA targeting TRMT10A (siTRMT10A #1) alone or in combination with 
siRNA targeting Bim (siBim) in cells treated for 24 hours with palmitate (TG). Data are 
expressed as mean ± SEM (n = 4-8). * p<0,05 vs siCT(CT), # p<0.05 vs siCT(TG), £ 
p<0,05 vs siTRMT10A(TG) 
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5 DISCUSSION 
The present work describes the study of tRNA modifying enzymes in 
pancreatic beta cells. tRNA molecules have a crucial role in protein 
translation and several reports have recently shown that tRNAs can act as 
signal molecules in response to environmental stresses. The maturation, 
the stability and the function of tRNAs are highly regulated by post-
transcriptional modifications of nucleotide residues and methylation is the 
most common modification. Mutations in genes encoding tRNA modifying 
enzymes have been associated to different diseases. Even if the 
modification of tRNA residues is a ubiquitous phenomenon, mutations in 
tRNA modifying enzymes can affect specific tissues or cell types, 
depending on differential expression levels or on specific feature and 
functions of cells. The main objectives that have been driving my PhD 
research project are:  
Ø The identification of a new candidate gene for congenital 
hyperinsulinism through the characterization of the S561F variant of the 
methyl-thio transferase CDKAL1; 
Ø The study of the role of the methyl transferase TRMT10A in human 
cells and the investigation of consequences of TRMT10A deficiency on 
pancreatic beta cells survival.  
The Cdk5 regulatory associated protein 1 (CDKAL1) was previously shown 
to have a central role in regulation of beta cell function. The enzyme 
catalyzes the methyl-thiolation of N6-threonylcarbamoyladenosine (t(6)A), 
leading to the formation of 2-methylthio-N6-threonylcarbamoyladenosine 
(ms(2)t(6)A) at position 37 in tRNAs. tRNAs specific for lysine are modified 
by CDKAL1 and this modification is required to ensure fidelity in the 
incorporation of lysine residues in nascent polypeptides during protein 
translation. Polymorphisms in CDKAL1 gene are associated with the 
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development of type 2 diabetes; functional studies using an islets-specific 
knock out mouse model determined the key role of CDKAL1 in beta cell 
function. The enzyme resulted to be important for the correct maturation of 
pro-insulin, regulating the fidelity of lysine residues incorporation in 
cleavage sites of the protein. CDKAL1 knockout mice show impaired insulin 
secretion and develop diabetes. The S561F variant of CDKAL1 was 
identified in a whole exome sequencing (WES) study of congenital 
hyperinsulinism patients. Congenital hyperinsulinism is a rare disease, 
caused by mutation in genes involved in different steps of glucose 
stimulated insulin secretion process. The genetic causes have been 
defined in only the 50% of patients and WES studies are useful to identify 
novel causative genes. I managed the gene list derived from WES using a 
candidate gene prioritization tool, identifying CDKAL1 as one of the most 
promising genes, significantly enriched in different functional categories. 
The possible consequences of the variant were investigated using 
bioinformatics tools and databases. The non-conservative aminoacid 
change affects the C-terminus of the protein and the residue 561 is part of 
the hydrophobic domain that forms the trans-membrane α-helix inserted in 
the endoplasmic reticulum membrane. Using the HeliQuest tool I performed 
an in silico prediction of the organisation and the characteristics of the wild 
type and mutated α-helix, finding that the substitution of a serine residue 
with a phenylalanine leads to an increase of hydrophobicity and decrease 
in the hydrophobic moment. The hydrophobic moment is important to 
predict the amphiphilicity of the α-helix that defines the spatial distribution 
and the orientation of the hydrophobic and hydrophilic residues of the 
domain. The conclusions derived from bioinformatics studies are that the 
mutation identified in CDKAL1 could participate in the development of 
inappropriate insulin secretion phenotype because of the functional role of 
CDKAL1 in beta cells; furthermore the S561F variant modifies key features 
	   	  68	  
of the trans-membrane domain, suggesting possible consequences on the 
localization and retention of the protein in the ER-membrane. The beta cell 
line INS-1E was used as model for in vitro studies of CDKAL1 variant. Cells 
were stably transfected with expression vectors encoding the wild type or 
the S561F variant of CDKAL1 fused with a hemoagglutinin (HA) tag. 
Results derived from immunofluorescence microscopy showed that the 
S561F CDKAL1 variant still localizes in the ER but presents an abnormal 
accumulation in spots of the ER membrane. It’s still unclear if the abnormal 
localization pattern could have a role on the modulation of protein stability 
and turnover. To address this question ongoing experiments aim to 
investigate the stability of the protein in the ER membrane. INS-1E cells will 
be transfected transiently and collected at different time points. The 
expression of the protein will be evaluated in total protein lysates and/or in 
isolated ER fractions. INS-1E clones were also used to investigate whether 
CDKAL1 variant could affect beta cell function. Interestingly, insulin content 
is increased by the over-expression of wild type but not of mutated 
CDKAL1.  On the other hand the insulin secretion results to be increased 
by the overexpression of mutated CDKAL1 in basal conditions. Further 
analysis are necessary to confirm if the mutation can leads to beta cell 
dysfunction and which is the mechanism involved. To pursue this objective 
experiments will be performed to evaluate the insulin secretion in a range 
of glucose concentrations in wild type and mutated INS-1E clones. The 
incorporation of lysine residues in pro-insulin has been shown to be 
necessary for the correct maturation of the protein, furthermore CDKAL1 
was found to be important for the expression of precursors of secretory 
granules proteins, pro-CGA and pro-ICA51256. The modulation of granules 
proteins expression and maturation can be the mechanism involved in 
CDKAL1-dependent modulation of insulin secretion. Further studies will 
investigate the direct consequence of S561F CDKAL1 variant on granules 
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proteins. Lysine incorporation in immunoprecipitated pro-insulin and 
granule proteins will be evaluated in cells overexpressing the wild type and 
the mutated form of CDKAL1.  
Preliminary results presented in this work suggest that the S561F variant of 
CDKAL1 could have a role in the development of beta cell dysfunction, but 
further confirmations are needed to associate this variant with the 
development of congenital hyperinsulinism. 
A mutation in the gene encoding the methyl-transferase TRMT10A was 
identified in patients affected from a new syndrome of microcephaly and 
young onset diabetes. Three patients derived from a consanguineous 
family showed to have the same homozygous non-sense mutation 
Arg127stop in TRMT10A gene that leads to the complete absence of 
mature protein and mRNA non-sense mediated decay57. In addition a 
homozygous missense mutation Gly206Arg in TRMT10A was identified in 
siblings affected by abnormalities in glucose homeostasis and 
microcephaly58. Another recent report described one patient affected by a 
syndrome of intellectual disability, delayed puberty and diabetes 
characterized by the deletion of TRMT10A gene59. All these evidences 
support the hypothesis that TRMT10A function is necessary for beta cell 
homeostasis. However the function of TRMT10A in human cells is still not 
clarified. The yeast homolog of the protein is a methyl-transferase that 
modifies tRNAs molecules at the level of G9 residues. Lymphoblast cells 
derived from control subjects, one heterozygous carrier and one patient 
with Arg127stop mutation of TRMT10A were used to investigate the 
function of the protein in human. Lymphoblasts are a good experimental 
model since they are easy to obtain and maintain in culture and they have 
the same genetic background of the donors. Mass spectrometry analysis of 
samples derived from lymphoblasts showed that there was a decrease of 
tRNA methylation in TRMT10A deficient patient. However the technique 
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doesn’t allow us to identify which tRNA molecules are missing the 
modification. tRNA purified from lymphoblasts samples was used for the 
primer extension assays. Between the tRNA molecules that present a 
guanine residue in position 9, only the tRNAs specific for glutamine 
(tRNAGLN) and for the initiator methionine (tRNAiMeth) resulted to not 
methylated in the patient. This result is the first evidence that human 
TRMT10A catalyzes the methylation of specific tRNAs in vivo in guanine 9 
of tRNAs. It’s known that nucleotide modifications can affect the function, 
the stability and the aminoacylation of tRNAs. A northern blot technique 
was set up in order to detect specific tRNA molecules through the 
hybridization with radiolabeled probes. The extraction of total RNA from 
lymphoblasts in acid conditions allows preserving the aminoacylation of the 
molecules. Preliminary northern blot results showed a slight decrease of 
the amount of tRNAiMeth and tRNAGLN, substrates of TRTM10A, in 
lymphoblast from one patient. This observation needs to be confirmed 
analyzing a second patient and more controls. Suitable positive controls 
are also necessary to verify if the technique allows the identification of 
partially deminoacylated tRNAs. Previous studies in yeast reported that the 
absence of non-essential modifications of tRNAs affect the maintenance of 
tRNA aminoacylation after heat-induced stress that triggers the unfolded 
protein response67. Furthermore TRMT10A deficiency induces a pathologic 
phenotype that involves mainly pancreatic beta cell dysfunction and 
neurological abnormalities, suggesting tissue and cell specific 
consequences of the absence of the enzyme. For this reason it will be 
necessary to repeat the experiment with samples derived from TMRT10A 
knock out beta cells in control conditions and treated with different 
stressors, such as free fatty acid or chemical ER stressors. In addition, 
improving the northern blot technique may allow the detection of small 
fragments of tRNAs (tiRNAs). The amount of tiRNAs in cells is modulated 
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by environmental stress and this mechanism can regulate cell survival44. 
Furthermore tiRNAs can act as microRNA regulating gene expression46. 
Previous in vitro studies have demonstrated that TRMT10A deficiency 
doesn’t affect insulin secretion from beta cells, but induces apoptosis and 
sensitizes cells free fatty acid and chemical ER stressors57. The hypothesis 
derived from these observations is that TRMT10A deficiency can lead to 
the development of diabetes by affecting the survival of beta cells. To 
understand which mechanism is involved in TRMT10A deficiency I used 
TRMT10A knockdown-beta cells as experimental model. TRMT10A 
silencing-induced apoptosis was confirmed in INS-1E cells using three 
different siRNAs. Importantly all the results obtained in INS-1E cells were 
confirmed in the human beta cell model EndoC-βH1 cell line. It was 
previously shown that activation of the intrinsic pathway of apoptosis leads 
to beta cells loos during the development of diabetes68. My results show 
that TRMT10A deficiency leads to the increase of Caspase 9 cleavage, a 
marker of the intrinsic pathway of apoptosis, in rat and human beta cells. 
The pro-apoptotic BH3-only family members are mediators of the intrinsic 
pathway of apoptosis activating Bax and Bak effectors that form pores in 
the mitochondrial outer membrane with consequent cytochrome c release 
and caspases activation. Different pathways, in response to apoptotic 
stimuli, can regulate the function of BH3-only proteins. I evaluated the 
expression of the BH3-only members Bim, Bad, DP5 and Puma at mRNA 
level in INS-1E cells, finding that the expression of the sensitizer Bim and 
the activator Bad was induced by TRMT10A silencing. However only Bim 
resulted to be modulated at protein level, with an increase of expression, 
especially of the most pro-apoptotic isoform BimS, produced by alternative 
splicing. These findings were confirmed in EndoC-βH1 cells. Furthermore 
Bim silencing protected cells from TRMT10A knockdown-induced 
apoptosis. It was previously shown that TRMT10A expression is induced in 
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INS-1E in response to palmitate and chemical ER stressors and that 
TRMT10A silencing sensitizes cells to palmitate-induced apoptosis. 
Palmitate is one of the most common long chain free fatty acid that 
represent the main environmental factor leading to beta cell apoptosis in 
type 2 diabetes through ER stress. Bim knockdown resulted to be 
protective also against TRMT10A knockdown-induced sensitization of INS-
1E cells to palmitate. Since EndoC-βH1 cells are not sensitive to free fatty 
acid (not published observation from our group), these cells were treated 
with the SERCA pump inhibitor thapsigargin to induce ER stress response. 
My results showed that the expression of TRMT10A was induced by 
thapsigargin treatment in human beta cells. TRMT10A silencing sensitizes 
in EndoC-βH1 cells to apoptosis after thapsigargin treatment and the role 
of Bim in the process was confirmed.  
My results demonstrated that TRMT10A deficiency affects beta cell 
homeostasis mainly through the activation of the intrinsic pathway of 
apoptosis. It’s still unclear which is the mechanism that leads to the 
activation of Bim. Bim function is modulated though the regulation of gene 
expression and splicing. Three are the major isoforms and all of them 
induce apoptosis. However the shortest isoform (Bim S) is the most potent 
since it can directly bind the pro-apoptotic effector Bax and is not 
sequestered to the cytoskeleton as the bigger isoforms Bim EL and Bim 
L69. Bim gene transcription is regulated from different transcription factors: 
FoxO3a, E2F1, STAT1, c-Myc, NF-Y, Smad1/3, Runx1-3, c-Jun and RelA 
induce Bim while YY1, HoxB8, SPi-1/PU.1, PINCH-1 and Pokemon are 
inhibitors of Bim expression. Several proteins can also regulate the 
splicing. In beta cells the splicing factor SRp55 leads to increased 
expression of BimS and apoptosis. Moreover several microRNAs have 
been shown to modulate Bim expression. Another major regulatory 
mechanism of Bim-dependent apoptosis is driven by phosphorylation. 
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Phosphorylation may either increase its activity (e.g., by JNK), or promote 
its degradation (e.g., by ERK/MAPK) resulting in pro-survival effect. Due to 
the complexity of this process further studies are necessary to understand 
which mechanism regulates Bim function and apoptosis as a consequence 
of TRMT10A deficiency. Interestingly recent observations showed that 
tiRNAs can interact directely with cytochrome c modulating the intrinsic 
pathway of apoptosis as a consequence of environmental stress70. 
Hypomethylation also may lead to tRNAs fragmentation triggering cellular 
stress responses71. Based on that future studies will investigate the role of 
TRMT10A-mediated modification in tRNA cleavage. 
During the last years several reports highlighted the crucial role of tRNA 
modifications in modulation of cellular homeostasis and response to 
environmental factors. The results achieved and described in the present 
work supply new evidences of the role of tRNA modifying enzymes in beta 
cell function and survival even if further studies are necessary to fully 
understand the molecular mechanisms that are involved. In summary the 
study of monogenic diseases represents a good model for the identification 
of novel pathways involved in beta cell demise.  
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